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ABSTRACT 
Jing Fu: The Role of Carboxylesterases in the Biotransformation of a Radionuclide  
Decorporation Agent DTPA Penta-ethyl Ester Prodrug  
(Under the direction of Michael Jay) 
 
A penta-ethyl ester prodrug of diethylenetriaminepentaacetic acid (C2E5) was developed 
for radionuclide decorporation. Previous studies of C2E5 delivered by oral and transdermal 
routes in rats suggested that the prodrug is metabolized to C2E2, and not the active drug DTPA. 
Although it was later determined that C2E2 is an active drug, it is unknown if C2E5 is converted 
into C2E2 and/or DTPA in humans, and whether C2E5 metabolic mechanisms affect its delivery. 
Therefore, the objectives of this study were to investigate the hepatic, intestinal and plasma 
hydrolysis of C2E5 hydrolysis in preclinical species and humans, identify the human CESs 
(CESs) isoforms that hydrolyze C2E5, evaluate the biotransformation of C2E5 by CESs in 
human skin, and determine the effect of excipients on transdermal C2E5 hydrolysis.  
Hydrolysis of C2E5 was assessed using S9 fractions from human, dog and rat tissues, and 
human recombinant CESs in the absence or presence of an esterase inhibitor. The data revealed 
interspecies differences in C2E5 metabolism caused by differences in CES expression profiles, 
and demonstrated that C2E5 metabolism in dog and rat is not representative of its metabolism in 
humans. Therefore, further studies were conducted using S9 fractions from human keratinocyte 
cell lines and CES-specific inhibitor to determine the contributions of individual CESs to C2E5 
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metabolism in human skin. Data analysis by LC/MS/MS revealed that C2E5 is hydrolyzed by 
CESs in human keratinocytes, with a primary metabolic role for CES1.  
 Since cutaneous metabolism contributes to C2E5 transdermal delivery, 12 common 
excipients used in transdermal formulations were analyzed for their potential to alter C2E5 
hydrolysis by human skin. Significant inhibition of C2E5 metabolism was observed with 
Miglyol 840, Eudragit RLPO, Crodamol EO-LQ-(MH), Brij 72, sodium lauryl sulfate and Tween 
20, at concentrations of 100 µg/ml, whereas Eudragit RSPO enhanced C2E5 hydrolysis.  
Overall, this research project provides important insights into C2E5 metabolism through 
oral and transdermal delivery routes in humans that could impact multiester-based prodrug 
development.   
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CHAPTER 1: INTRODUCTION 
 
1.1 General Introduction 
	  
The development of prodrugs started in the early 20th century, with prodrugs expanding 
into multiple aspects of medicinal therapy: chemotherapy, ACE inhibitors, diabetic therapy and 
antibiotics. The use of prodrugs is a common strategy applied to improve absorption, disposition, 
metabolism and excretion (ADME) properties of therapeutic medicines: for example, adding a 
new moiety to obtain the balance of the lipophilic-hydrophilic properties of drug. Hydrophobic 
drugs usually need to be structurally modified by adding a hydrophilic moiety. For example, 
fenofibric acids, used in clinics to reduce fatty acids in the blood, are covalently conjugated to 
symmetrically branched oligoglycerols (BGL), resulting in increased water solubility by two 
thousand fold compared to applying fenofibric acid alone. This BGL conjugated fenofibric acid 
prodrug has displayed improved pharmacological efficacy and pharmacokinetic properties but 
with increased toxicity 1 . In contrast, ester or amide groups can be used to mask polar ionized 
groups to improve the drug absorption. For example, pivaloyloxymethyl phosphoric acid ester of 
adefovir has four times greater bioavailability than adefovir 2 . Among all the ester-based 
prodrugs, carboxylic acid ester prodrug strategy is widely used to significantly improve water-
solubility, cell membrane permeability, and bioavailability. 
Prodrugs are pharmacologically inactive and thus need to be converted to active drugs by 
endogenous enzymes for treatment. Consequently, prodrug designs are strategically tailored to 
be biotransformed by metabolic enzymes, for example, cytochrome P450 reductase, cytochromes
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P450, hydrolase and glutathion S-transferase 3 . It is necessary to study metabolic enzyme-
mediate activation of prodrug to verify the effectiveness of prodrug design.  
 Prodrug development requires strict compliance with FDA regulatory guidance. Drugs 
are tested in pre-clinical animal models before clinical trials; however, careful consideration is 
needed for selection of the appropriate animal model required for the first-dose calculation in 
human trials. Especially, interspecies differences exist in-between animals and human. Metabolic 
studies should be carried out in one rodent and one non-rodent. The study results from the 
representative animal model for a specific compound are important indicator for the prediction to 
human. Metabolic enzyme isoform differences in expression are associated with interspecies 
difference in drug metabolism.  For example, the species-specific isoforms of CYP1A, 2C, 2D 
and 3A exhibit interspecies differences in catalytic activity and some adjustments are necessary 
in order to extrapolate data from animal models to humans 4 .  
Currently, drug metabolism is investigated in major metabolic sites  
(liver, intestine, and plasma). Fewer published reports have examined metabolism through the 
skin. Small molecular weight drugs have been reported to be bio-transformed in the epidermal 
layer of the skin. For example, theophylline that is used as a treatment for respiratory disease was 
metabolized in skin, which resulted in enhanced absorption and improved the therapeutic effect 5 
. Phase I and II metabolic enzymes that are also responsible for prodrugs activation presented in 
skin. Their role in metabolism by transdermal delivery varies, which dictates ADME properties 
of the administered compounds. Different approaches can be applied to assess skin metabolism. 
Reconstructed skin models, for example, Graftskin™ LSE™ (living skin equivalent) and the 
Skinethic™ HRE (human reconstructed epidermis), are commonly used 6 . Even thought skin of 
pig has been considered as one of the most appropriate models for human, the species differences 
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in cutaneous metabolism still impact the predictability of the dermal absorption of drug from pig 
to human.  7,8 . Therefore, the characterization of the enzyme expression and activity in human 
skin tissue and human cell models are considered as a necessary approach.  
Excipients are crucial component for transdermal drug delivery formulation. Non-ionic 
excipients are usually used in cream or gel formulation. They can be easily mixed with active 
pharmaceutical ingredients (API) or prodrugs to obtain a zero-order release rate. On the contrary, 
their non-ionic properties can sometime resulted in difficulty in bio-degradation. The complex 
chemical structure can interact with biological components easily, for example, enzymes. The 
unpredicted interaction between excipients and metabolic enzymes could alter release and 
clearance pathways of prodrugs. Therefore, it is important to understand the effects of excipients 
on transdermal delivered drug’s efficacy and toxicity. Those discussions set an initial platform 
for this dissertation work illustrated in the subsequent chapters.  
1.2. Decorporation of Radionuclide Contamination  
	  
Radiation hazards usually are known as ionizing radiation, produced by nuclear reaction, 
nuclear reactor industry waste and nuclear weapons from terrorists. Examples include lethal 
effects to individuals, large radioactive release to the environment or reactor core melt. Nuclear-
related accidents have been reported worldwide. The major radiation incidents reported in 
history include accidents of nuclear power plants and radionuclides such as, Fukushima Daiichi 
(2011) 9 , Goiania accident (1987) 10 , and Chemobyl (1986) 11 .  These incidents resulted in 
exposure to large populations and resulted in a variety of medical needs and the demand of 
urgent and effective treatment.  
Ionizing radiation emits particles that pass human body that push electrons out of the 
orbit around the atom or nucleus from DNA or other vital molecules in tissues to cause damage.  
	  4	  
On the other hand, radiation can also create free radicals by ionizing water molecules in body 
fluids. The free radicals mutate DNA and disrupt cell reproduction, which can lead to cancer. If 
the damage occurs in germ cells, it usually results in hereditary disease to the unborn children 12 .  
The greatest concerns are transuranic elements that are chemical elements with atomic 
numbers greater than uranium (92), which are unstable and radioactive. The development of 
Americium (Am), plutonium (Pu), and curium (Cm) for the use in nuclear plant, weapon, and 
wastes are the sources of the threats.  
 The possible spread of radioactive material over a populated area has made the 
development of medical countermeasures against these threats a national security priority. The 
National Institute of Health has been leading an effort to identify innovative therapies that can be 
included in the US Strategic National Stockpile for distribution to populations affected by an act 
of nuclear terrorism. Among them, Am, Pu and Cm have been ubiquitously applied to nuclear 
power plants and other usages.  In the history of the United States, a number of people who have 
worked in the plutonium industry since the Manhattan project had higher chance of radiation 
exposure or contamination.   Radioactive elements can enter the human body by a few different 
routes, for example, inhalation, skin absorption, minor cuts and abrasion. After a radioactive 
element enters into the blood, the element is predominantly deposited in the liver and skeleton, 
where retention appears to be prolonged.  The current methods of removing accidental intakes of 
actinides from the body are moderately successful. If insoluble materials are inhaled, 
bronchopulmonary lavage is the effective treatment.  If the actinides are localized, the removal of 
damaged tissue is recommended.   
The chelating agent, DTPA (Fig 1.1), approved by FDA, is used for the treatment to 
eliminate soluble forms of plutonium, americium and curium for internal contamination. The 
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intravenous (IV) injection of either Ca-DTPA or Zn-DTPA (Fig 1.2) effectively clears actinides 
from the blood and extracellular fluids where they are finally removed via urination 13 .  
Other than IV injection treatment, inhalation therapy of Ca-DTPA was developed by 
Yutaka Jin. He managed to deliver 26% of Ca-DTPA by aerosol route to trachea and lung. A 50 
mg inhalation of DTPA is a recommendable safe dosage. However, DTPA should be still 
administered once the dose of actinide is greater than 20mSv 14 . Gervelas reported to the 
development of lung delivery of a dry powder formulation of DTPA 15 .  In addition, Ca-DTPA 
and Zn-DTPA have been formulated in minicapsules at Lawrence Livermore National 
Laboratory 16 . The FDA suggests that Ca-DTPA should be used as a first dose, following Zn-
DTPA as a preferred treatment for maintenance because Ca-DTPA can cause essential mineral 
loss.  
The working mechanism of chelation is based on coordination chemistry. Chelating 
agents are organic or inorganic compounds that are competent in binding to metal ions to form 
complex ring-like structures as ‘chelates’.  Atoms like sulfur (S), nitrogen (N), and oxygen (O) 
function as ligand atoms in the form of chemical groups like –SH, -S-S, -NH2, =NH, -OH, -
OP3H, or >C=O 17 . Chemical properties of ideal chelators include: high affinity and minimal 
toxicity, ability to penetrate cell membranes, rapid elimination, high water solubility, resistance 
to other biotransformation, ability to reach the sites of metal storage, retain chelating ability at 
the pH of body fluids and have the ability to form metal complexes that are less toxic than the 
free metal ion 17 . Ethylenediaminetetraacetic acid (EDTA) can be used in chelation, however 
DTPA has better affinity to metals because DTPA has five carboxylic acids in comparison to 
four for EDTA. The carboxylic acid groups act as claws to binds to metal ions by forming eight 
	  6	  
coordinate bonds. The stronger the binding, the better the sequestration of the ions for 
elimination.  
1.3 Oral Formulation of Prodrug C2E5  
	  
C2E5 (MW=533.61232 (g/mol), Log P=3.3) was developed for oral formulation in our 
lab previously. The orally available route is natural, easy and safe. It is convenient for patients 
and can be self-applied. The strategy to develop DTPA prodrug (C2E5) improved the 
undesirable low lipophilicity of DTPA to high lipophilicity and improved the pharmacokinetic 
properties (rapid excretion) of DTPA. It is known that esterases are expressed in the liver, 
intestine and plasma and they can readily cleavage prodrugs in the metabolic organs help to 
sustain the long-term effect of the activated prodrugs. Sueda’s result has shown that oral delivery 
of C2E5 produces a higher pharmacological effect on rats 18 . The maximum tolerated dose study 
demonstrated that the adverse effects were only observed in animals at ten times of the effective 
dose of C2E5. Oral delivery of C2E5 is 66% as effective as an equivalent i.v. delivery of DTPA 
in decorporating 241Am when C2E5 is administered at 30 mins right after contamination 19 . 
Therefore, oral treatment is much preferred even if it is not as effective as i.v. DTPA. However, 
the partially effective delivery using oral route is still advantageous to FDA approved 
formulation due to its self-administered nature.  
1.4 Transdermal Formulation of Prodrug C2E5 
	  
  C2E5 was developed for transdermal delivery in our lab previously. The C2E5 non-
aqueous gels that are comprised of 40% C2E5, 40-45% Miglyol 840 and 15-20% ethyl cellulose 
and prepared by solvent evaporation method proved to be effective by the evaluation of mass 
balance study and in vivo decorporation study in rodents 20 . The pharmacokinetic data in rat 
from Zhang’s studies demonstrated that non-aqueous gel transdermal delivery of C2E5 resulted 
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in a higher systemic exposure to C2E3 and C2E2, (metabolites of C2E5), compared to oil 
formulation. Advantageously, C2E5 was metabolized into a newly discovered active drug C2E2 
in rat 21,22 .  
1.5 The Role of Metabolism Studies in Prodrug C2E5 Development  
	  
In order to find out whether a prodrug strategy works, it is necessary to investigate 
metabolism, pharmacokinetics, safety and toxicity which are necessary prior to human clinical 
trials. In most of the cases, the outcomes of this research help to evaluate the efficacy of 
prodrugs, identify potential toxic metabolites, and estimate a safe starting dose of the drug for 
human. As C2E5 would be used for radionuclide decorporation, it cannot be tested in humans 
due to ethical limitations. Therefore, metabolism studies (metabolism kinetics, mechanisms and 
drug-excipient interactions) provide important information. Meanwhile, the discovered metabolic 
information can be used for prodrug candidate optimization.   
1.6 Interspecies Differences in Drug Development   
 
In drug development, animal models are used in the preclinical development of new 
drugs to predict the metabolic behavior, toxicity, exposure, response, and first-time dose in 
human trials. Appropriate surrogate species need to be utilized for different purposes 
respectively.   
Humans are different from animals at anatomically and molecularly. The isoforms of the 
enzyme’s composition, expression and catalytic activities tend to be different among all the 
species. This leads to different metabolic or toxicological profiles in animals compared to 
humans. For example, paclitaxel, a drug used to treat cancer, was evaluated in rats and humans. 
However, results indicated that different metabolites were formed in the rat and human 23 . The 
metabolites found in rats which caused drug-drug interactions did not exist in human metabolism 
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pathways, and paclitaxel, was subsequently developed and approved for cancer treatment 
Another example is zidovudine. Rapid glucuronidation in humans produced a much shorter half-
life than expected from studies in animals. As a result, the drug was excreted at different rates in 
humans and animals, which leads to different drug exposure in species 23 . Iododeoxydoxorubicin 
is another example.  The parent molecule predominates in mice, in contrast to metabolites of 
iododeoxydoxorubicin predominates in human 23 .  If the interspecies differences had not been 
investigated, in the above examples, then scientists would misleadingly extrapolate experimental 
results in animals to human. Numbers of different factors are necessary to be examined while 
studying species differences in drug metabolism. These factors include tissues binding affinity or 
plasma components, types and amount of drug-metabolizing enzymes present in each species, 
and the volume of distribution.   
Therefore, the study of interspecies differences in drug metabolism will help to 
accurately elucidate drug action in human from those obtained from animal data alone. Common 
experimental approach is to use S9 fractions for physiological disposition and metabolic fate of a 
compound in multiple species over short amount of duration. Another approach is to use specific 
inhibitors and inducers to decrease or increase the metabolic enzyme activity in different animals 
that normalize the metabolic patterns to that of humans. The third way to examine potential 
interspecies differences is to use humanized mice 24 , which are commonly used as small animal 
models in biological and medical research for human therapeutics. Immunodeficient mice (SCID 
mice) are often used as the animal for incorporating human cells or tissues to create humanized 
animal models. Mainly, those mice produce minimum immune response to heterologous cells 
due to the fact that they are lack of immunity.  
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1.7 CESs Isoform in Drug Metabolism  
	  
  CESs (Fig 1.3) are members of the serine hydrolases, that have five subfamilies (CES1-
CES5) according to the Hosokawa classification 25 . CESs are ubiquitously expressed and 
distributed abundantly in the liver, kidney, small intestine, brain, nasal and mucosal passages, 
lungs, testicles, and saliva 26 . The catalytic triad (Ser-Glu-His) assists cleavage using a two-step 
process, which involves the formation and degradation of an acyl-enzyme, intermediate 27-29 .  
CESs work to break down endogenous lipids and cholesterol, hydrolyze biochemicals, 
such as acylcarnitine, palmitoyl-CoA, mono and diacylglycerols, and chaperone and carry 
proteins in the endoplasmic reticulum. The most important isoforms involved in phase I drug 
metabolism are CES1 and CES2. CES1 is expressed the highest in the liver, while CES2 is 
highly expressed in the small intestine 30-32 . The expression and activity of CES1 and CES2 
affect the ADME of the ester-based or amide-based prodrugs, which consequently influence the 
pharmacological efficacy and toxicological profiles of the drugs in patients.  
CES1 and CES2 exhibit 48% sequence identify. However, different substrate preferences 
have been reported in the literature. CES1 prefers substrates with large acyl and small alcohol 
moieties, while CES2 prefers substrates with smaller acyl and bulky alcohol moieties 31,33 . 
Interestingly, substrates for CES2 can also be substrates for CES1, in contrast substrates for 
CES1 are not necessary a substrate for CES2. Thus, CES1 metabolizes a wider range of 
substrates compared to CES2.  
Ester-based prodrugs are expected to be hydrolyzed very rapidly in tissues where 
expression of CES is high. Therefore, understanding of the mechanisms behind the metabolism 
of C2E5 by the liver and skin will help the development of more potent and effective prodrugs.  
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1.8 Skin Metabolism in Transdermal Delivery  
	  
Skin (Fig 1.4) the largest organ in human body, has been used as a target for application 
of cosmetics and pharmaceutical delivery because its anatomical advantage. Human skin is 
comprised of the epidermis and dermis. The epidermis has three main types of cells: 
keratinocytes (skin cells), melanocytes (pigment-producing cells) and Langerhans cells (immune 
cells). The epidermis layer varies from 50 μm to 1.5 mm thick 34 , depending on the location on 
the skin. The stratum cornium in the epidermis is the major barrier for transdermal delivery. 
Keratinocytes make up most of the epidermis, and are also known as highly specialized 
squamous stratified epithelium. Keratinocytes do not have nerves to go into them; therefore, they 
need to have a very dynamic enzyme environment to transport nutrition. It is understandable why 
keratinocytes express considerable amount of a diversified group of metabolic enzymes, as their 
role is to degrade harmful environmental compounds.  
There are two major pathways for dermal absorption: intercellular and transcellular 
penetration (Fig1.5). Small molecular compounds are usually transported transcellularly by 
passive diffusion, mainly following Fick’s law of diffusion 35 ; Skin permeation of 
macromolecular is very difficult.  
Hydrolysis of topically applied esters is important for the activation of prodrugs. Clark 
showed that both the epidermal and dermal layers of human skin have the capacity to hydrolyze 
esters. It has previously been shown that human skin CESs are located at the basal layer of the 
epidermis 36 . The amount of metabolizing enzymes in the skin is generally lower compared to 
the major site of metabolism, the liver 37 , nevertheless, esterase and phase II enzymes that are 
expressed in the skin may influence systemic delivery of transdermal drugs.  
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Skin has been known to possess a considerable nonspecific esterase activity, which has 
been exploited for the delivery of ester prodrugs. CESs are located at rat skin cytosol and 
microsomes. Moreover, much higher amounts of drug metabolizing enzymes were found in 
keratinocytes. In most studies, the keratinocytes were shown to be the major site of drug 
metabolism in the skin 38 .  
The rate of metabolism is influenced by a balance between the capacity of an enzyme to 
metabolize the chemical and the accessibility of the drug to the metabolic enzymes. This is the 
reason that rapidly diffusing drugs are generally less easily metabolized than slowly diffusing 
drugs. Biological monitoring of urinary metabolites generally reflects the metabolism in the liver 
rather than skin metabolism even for a dermally absorbed dose 26,37 .  
Inhibition studies with loperamide have suggested that hCES2 is expressed in human skin 
microsomes and cytosol 39,40 . It has been reported that human skin expresses mainly the CES1 
isozyme, and to a lesser extent CES2 isozymes.  Zhu et al. has reported a higher expression of 
hCE2 41  and a weaker expression of hCE1 in human HaCaT keratinocytes. Esterases, including 
CESs, are rarely investigated in animal skin 42 .  
The common approaches for cutaneous metabolism are to use cell models or 
reconstructed skin model. Monolayer cell cultures are frequently used in vitro to evaluate toxic 
effects. Usually they could overestimate the toxic effects of tested compounds, because cell 
cultures are lack of physiologically cellular interactions, which make them a less valuable 
predictor of the clearance of xenobiotic. Both human-cell derived reconstructed human epidermis 
(RHE) and reconstructed full thickness human skin (RHS) can imitate the native human skin, 
which could be alternative approaches for human skin metabolism and absorption studies. 
However, the application of S9 fractions derived from keratinocytes can successfully used to 
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investigate scientific questions related to keratinocytes specifically.  Since keratinocyte process 
the most metabolic enzymes at epidermis, it is reasonable to investigate cutaneous metabolism 
from this cell models.  
Few keratinocytes cell lines are representatives for study: human keratinocyte cell line 
HaCaT, HEKn, HEKa and A431 cell lines. Among them, HaCaT cells are derived as 
spontaneously transformed keratinocyte cell lines from adult human skin, widely used in 
scientific research. HaCaT cells are utilized for their high capacity to differentiate and proliferate 
in vitro. They have been used as a model system for vitamin D3 metabolism in skin 43 . Human 
Epidermal Keratinocytes, neonatal (HEKn) are the primary human epidermal keratinocytes 
isolated from neonatal foreskin from a single donor, which are cryopreserved at the end of the 
primary cells, with viability (>70%), and it also belongs to adherent cell type, which the cell 
grows as attached to the bottom of the cell culture flasks.  Human Epidermal Keratinocytes 
(HEKa) are adult primary human epidermal keratinocytes isolated from adult skin. A431 cells 
are a model human cell line (epidermoid carcinoma) used in biomedical research primarily for 
the study of cell cycles and cancer related cell signaling pathways.  
1.9 The Effect of Excipients in Transdermal Delivery 
	  
Drug formulations such as tablets, capsules, or injectable solutions consist of active 
pharmaceutical ingredients and other “inactive” ingredients that are added for multiple purposes. 
Excipients are added to preserve the medicine stability and to enhance its absorption for better 
efficacy. Interactions between the drug and excipients need to be carefully studied to ensure that 
the drug is stable in the formulation and that the solubility, as well as the dissolution properties in 
the case of orally administrated drugs, is satisfactory.  
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Not all the excipients in approved drug formulations are “inactive”, some are known to 
alter drug metabolism and/or transporter activities. Therefore, in the formulation development 
process, one needs to consider whether the chosen excipients in drug formulation can alter 
systemic exposure of the drug itself or affect other potentially co-administered therapeutic 
agents, due to interactions with drug-metabolizing enzymes and/or transporters. For example, it 
has been shown that Cremophor EL and Tween 80 decrease the intrinsic clearance of midazolam 
in rat hepatocytes by 30% and 25%, respectively. In another study, Cremophor RH40 inhibited 
CYP 3A-mediated nifedipine oxidation in human liver microsomes 44 . In addition, Cremophor 
EL in an oral paclitaxel formulation was found to reduce absorption of paclitaxel from the gut, 
presumably by micelle entrapment of the drug. Therefore, this study was conducted to examine 
whether any of the chosen excipients negatively affected the activity of CESs.  
1.10 Rationale for Proposed Research and Specific Aims  
	  
Even though Ca-DTPA/Zn-DTPA is effective, it is a challenge to arrange for trained 
medical professionals to administer intravenous medications, especially under emergency 
conditions. The benefits of developing ester-based prodrugs of DTPA include their ability to be 
delivered over many convenient routes and might provide an increase in bioavailability. Oral, 
transdermal and solid dispersion formulations of C2E5 have been developed in our laboratory. 
During development, concerns about the metabolism of C2E5 to an active drug when given via  
oral and transdermal routes have been discussed. It was anticipated that C2E5 would be 
metabolized in a stepwise fashion to DTPA by CESs. However, after both oral and transdermal 
administration, the primary metabolites detected in plasma were the tri-ethyl (C2E3) and di-ethyl 
(C2E2) esters of DTPA and thus C2E5 did not fully converted into DTPA. In order to further 
understand the potential conversion of C2E5 to DTPA in vivo, a number of questions arise.  
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What enzymes are responsible for metabolizing C2E5 and the metabolites of C2E5? Where are 
the enzymes located? Do the same or different enzymes convert the prodrug to the same extent in 
rat and human? Can we extrapolate the data from rat to human directly? Would skin metabolism 
be beneficial in enhancing the drug metabolism into an active compound? Would the addition of 
an excipient in the transdermal formulation be beneficial?  
Therefore, the present study aims to describe the mechanisms by which the prodrug, the 
penta-ethyl ester of DTPA (referred to as C2E5) is metabolized. Specifically, investigational 
studies focused on the interspecies differences in C2E5 metabolism, which determined the 
hydrolytic proficiency of human CESs on C2E5 metabolism, examined different isoforms of 
CESs expression in human skin tissue obtained from different cell lines to discover the 
contribution of cutaneous metabolism to C2E5 transdermal formulation. Additional studies were 
performed to examine whether excipients in transdermal formulations would affect CES-
mediated hydrolysis of prodrugs C2E5.  
Hypothesis:  
(1) Specific enzyme plays a role in C2E5 prodrug activation and metabolism in different 
species and tissue organs.  
(2) Specific enzyme in human skin cells and human S9 fractions metabolizes C2E5, which 
would enhance C2E5 transdermal delivery.  
(3) Excipients in transdermal formulations inhibit the metabolic activity of CESs and impede 
the hydrolysis of C2E5 in human skin S9 fractions.  
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The following specific aims were designed to test these hypotheses:  
Specific Aim 1: Investigate the interspecies differences in C2E5 hydrolysis and identify which 
of the CESs isoforms play an important role in C2E5 metabolism.  
1A. Evaluate the hydrolysis of C2E5 in liver, intestine, and plasma S9 fractions, from 
human, dog and rat.  
1B. Use CES1b, CES1c, and CES2 recombinant protein to evaluate CESs-mediated 
C2E5 hydrolysis.  
1C. Use inhibitors, bis (4-nitrophenyl)-phosphate (BNPP), to confirm the role of CESs in 
C2E5 hydrolysis. 
Specific Aim 2: Evaluate the biotransformation capacity of carboxylesterases in skin and 
keratinocytes for C2E5.  
2A. Characterize CESs genetic expression in HEKn, HEKa, HaCaT and A431 cell lines 
by RT-qPCR.  
2B. Evaluate CESs protein expression in HEKn, HEKa, HaCaT and A431 by western 
blot.  
2C. Evaluate CESs activity using the PNPA Assay and 4-NPV Assay.  
2D. Measure C2E5 hydrolysis in human keratinocyte S9 fractions and human skin S9 
fractions by HPLC and LC/MS/MS.   
2E.  Measure the specific CESs inhibitors effect on CESs-mediated C2E5 hydrolysis in 
human skin S9 fractions. 
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Specific Aim 3: Determine if any of the excipients used in transdermal formulations inhibit 
CES-mediated C2E5 hydrolysis.   
Those excipients are Miglyol 840, Miglyol 812, Eudragit RLPO, Eudragit RSPO, 
CrodamolTM EO-LQ-(MH), Capmul MCM, Capmul MCM EP, Captex® 355, 
polyoxyethylene tridecyl ether, Brij 72, sodium lauryl sulfate and Tween 20.  
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Figure 1.1 Diethylene triamine penta-acetic acid (DTPA). 
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Figure 1.2. FDA approved treatment (Ca-DTPA / Zn-DTPA) for 
Plutonium, Americium and Curium contamination.  
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Figure 1.3. Human CES1 crystal structure downloaded from protein data bank. 
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Figure 1.4. Human skin tissue anatomy available on: 
http://www.osovo.com/diagram/skindiagram.htm 
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Figure 1.5 Dermal absorption of small molecule. 
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CHAPTER 2 
INTERSPECIES DIFFERENCES IN THE METABOLISM OF A MULTI-ESTER PRODRUG 
BY CARBOXYLESTERASES  
2.1 Introduction 
 
The development of medical countermeasures is a national security priority due to the 
diversion of radioactive materials and the threat of nuclear terrorism. A number of potential 
terrorist threat scenarios have been envisioned, including the deployment of a Radiological 
Dispersal Device ("dirty bomb") that spreads radioactive material over a large populated area. Of 
particular concern are isotopes of the transuranic elements americium (Am), plutonium (Pu), and 
curium (Cm) due to their abundance and availability. The National Institutes of Health has been 
leading an effort to identify innovative therapies that can be included in the US Strategic 
National Stockpile for distribution to populations affected by an act of nuclear terrorism. The 
current strategy to reduce the absorbed radiation dose involves decorporation therapy to 
accelerate excretion of the contaminating radionuclide 1,2. Intravenous (i.v.) administration of 
either the calcium or zinc salts of diethylene triamine pentaacetic acid (Ca-DTPA/Zn-DTPA) has 
been approved by the US Food and Drug Administration (FDA) for contamination with Am, Pu, 
or Cm 3. To improve access to treatment, there is considerable interest in developing orally 
bioavailable chelators for the actinides. As a Class III compound in the Biopharmaceutics 
Classification System (high solubility, low permeability), DTPA is not a good candidate for oral 
delivery and can only be effectively given by i.v. administration.   
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Introduction of an ester linkage has been shown to enhance the systemic delivery of 
pharmacologically active compounds with low oral absorption due to high hydrophilicity 4-6. 
Therefore, in order to achieve higher oral bioavailability, a penta-ethyl ester DTPA prodrug, 
designated as C2E5, was synthesized. The five added ester moieties greatly increase the 
lipophilicity of DTPA, which is measured by increased CLogP. (CLogP of-2.7 for DTPA in 
contrast to ClogP of 4.7 to C2E5) Studies in rats confirmed that C2E5 shows enhanced oral 
bioavailability compared to DTPA, with extensive but incomplete metabolism 7 and can elicit 
effective radionuclide decorporation following oral 8 and transdermal delivery 9. Together, these 
findings suggest that this prodrug may be a useful and effective alternative treatment to DTPA. 
The enzymes responsible for C2E5 metabolism to DTPA have not previously been reported, but 
promising candidates for metabolism are the Carboxylesterases (CESs), which could sequentially 
cleave the five ester moieties to form the metabolites C2E4, C2E3, C2E2, C2E1, and DTPA as 
shown in Figure 1.  
Many of the ester-based prodrugs are biotransformed by carboxylesterases (CESs) (EC 
3.1.1.1), which are members of the α/β-fold hydrolase superfamily. CESs are grouped in five 
subfamilies (CES1–CES5) according to the homology of the amino acid sequence 10,11. The most 
prolific CESs belong to the CES1 and CES2 families, and are categorized as phase I enzymes 
important for metabolism of xenobiotics, including drugs and prodrugs. All CESs cleave esters 
via a two-step process that involves the formation and degradation of an acyl-enzyme 
intermediate. CESs exhibit ubiquitous tissue expression, but are predominantly expressed within 
the small intestine and liver consistent with their roles in biotransformation and detoxification. 
Carboxylesterase expression differs among species and organs within a single species, resulting 
in differences in substrate specificity 12,13. For example, rat plasma has high expression of CES 
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whereas the human and dog are lacking of CES activities 14. In addition to the differences in 
expression, species differences exist regarding to CES activity. In general, it has been shown that 
CES2 has much greater affinity for lipophilic substrates compared to CES1 13; meanwhile, CES1 
prefers small alcohol group compound and CES2 prefers bigger alcohol group compound. Those 
characteristics of CESs could have important implications for lipophilic ester prodrugs, such as 
C2E5.   
The increasing threat of nuclear and biological terrorism has led the FDA to expedite the 
development and approval of new drug and biological products. The Animal Efficacy Rule (21 
C.F.R. § 314.610, drugs) 16,17 states, “when efficacy studies in humans are unethical or 
infeasible, studies in animal models will typically be needed to provide the efficacy data required 
to support approval, licensure, clearance, or emergency authorization.” As new therapies are 
being developed that utilize these hydrolytic pathways, it is vital to understand the similarities 
and differences in CES activity between humans and preclinical models of drug disposition 18. 
Thus, establishment of a reliable animal model for assessing the efficacy of radionuclide 
decorporation therapy is critical. The goal of the current study was to identify potential species 
and tissue differences in the CES-mediated hydrolysis of the multi-ester prodrug C2E5. 
 
 
2.2 Material and Methods 
 
Chemicals and Materials. [14C]-diethylene triamine pentaacetic acid pentaethyl ester 
([14C]-C2E5; 50 mCi/mmol) was purchased from American Radiolabeled Chemicals, Inc. (St. 
Louis, MO). Sprague-Dawley rat intestinal S9 fractions, isolated from a single male were 
purchased from Celsis In Vitro Technologies (Baltimore, MD).  Pooled, mixed gender human 
(intestinal, hepatic), single male Beagle dog (intestinal, hepatic), and single male Sprague-
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Dawley (hepatic) S9 fractions were purchased from Xenotech, LLC (Lenexa, KS). All S9 
fractions were prepared in the absence of phenylmethanesulfonylfluoride. Human CES1 and 
CES2 supersomes were obtained from BD Biosciences (Woburn, MA). Human, Beagle dog, and 
Sprague-Dawley rat plasma was purchased from Lampire Biological Laboratories, Inc. 
(Pipersville, PA). Ultima-Flo AP scintillation fluid was obtained from PerkinElmer Life and 
Analytical Sciences (Waltham, MA). Acetonitrile (ACN) and bis-(p-nitrophenyl) phosphate 
(BNPP) were purchased from Sigma Aldrich (St. Louis, MO). 
C2E5 In Vitro Metabolism in Human, Dog and Rat Intestinal and Hepatic S9 
Fractions and Plasma. [14C]-C2E5 (50µM) was pre-incubated in 0.1 M phosphate buffer (pH 
7.4) for 5 min at 37°C. Reactions were initiated by the addition of intestinal or hepatic S9 
fractions (1 mg/ml) and were maintained at 37°C. Plasma (250 µl reaction volumes) was pre-
incubated for 5 min at 37°C. Reactions were initiated by the addition of 50 µM [14C]-C2E5 and 
were maintained at 37°C. Equivalent boiled S9 fractions were used as a blank to correct for non-
enzymatic C2E5 degradation. The reactions were terminated by addition of an equal volume of 
ice-cold ACN followed by centrifugation at 14,000 x g for 10 min at 4°C. The supernatant was 
transferred to HPLC vials for subsequent analysis.  
C2E5 Metabolism by Human CES1-b, CES1-c, and CES2. One µM of [14C]-C2E5 
was pre-incubated in 0.1 M phosphate buffer (pH 7.4) for 5 min at 37°C. Reactions were 
initiated by the addition of CES1-b, CES-c and CES2 recombinant supersomes. The final 
enzyme concentration was 1 mg/ml and maintained at 37°C. In all instances, equivalent boiled 
S9 fractions were used as blanks to correct for non-enzymatic C2E5 degradation. The reactions 
were terminated by addition of an equal volume of ice-cold ACN followed by centrifugation at 
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14,000 x g for 10 min at 4°C. The supernatant was transferred to HPLC vials for subsequent 
analysis.  
Inhibition Studies on C2E5 metabolite formation. Recombinant human supersomes of 
CES1-b, CES1-c, and CES2 (final concentration of 1 mg/ml) were incubated in the absence and 
presence of the esterase inhibitor bis (4-nitrophenyl)-phosphate (BNPP) at 100 µM. The final 
concentration of the organic solvent (methanol) was less than 1%.  
HPLC analysis of C2E5 and Metabolites. C2E5 and its metabolites were analyzed 
using a Shimadzu Prominence HPLC system equipped with a Perkin Elmer Radiomatic 625TR 
Flow Scintillation Analyzer. Two Chromolith® Fast Gradient columns (RP-18e 50 x 2 mm 
Sorbent Lot No. UM8507) were used in tandem with an Alltima Alltech HP All-Guard Cartridge 
(C18, 5 µm particle size, 2.1 x 7.5 mm). Mobile phase A consisted of water with 0.1% TFA and 
mobile phase B was ACN with 0.1% TFA. Six regions of interest in the radiochromatogram 
were identified with a linear 14-min gradient with a flow rate of 0.3 ml/min, 5-95% B over 8 min 
before returning to 5% B for the remaining six min.  Each sample (10 µl) was injected in 
quadruplicate.  The activity in each region that met the threshold criteria (peak height greater 
than 60 cpm) was determined and expressed as a percentage of the total activity in all regions.  
The regions of interest were as follows:  DTPA, 1.20-2.30 min; C2E1, 3.60-4.90 min; C2E2, 
4.90-5.60 min; C2E3, 5.60-6.50 min; C2E4, 6.50-7.30 min; and C2E5, 7.30-9.00 min.  
DATA ANALYSIS  
All assays were performed in triplicate and expressed as the mean ± S.D. Data were 
analyzed with one-way ANOVA test by using GraphPad Prism 5 software. (***) is designated 
for P<0.001. 
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2.3 Results 
C2E5 Hydrolysis Catalyzed by Human, Dog and Rat Intestinal S9 Fractions. As 
shown in Fig. 2A, C2E5 hydrolysis was minimal in human intestinal S9 fractions, with 
approximately 84% C2E5 remaining over the 2 h incubation, whereas no hydrolysis occurred in 
the dog intestinal fractions. Rat intestinal fractions metabolized 85% of the C2E5. The C2E5 
metabolic profile of human, dog and rat fractions was determined by a radiomatic HPLC assay 
and is shown in Figs. 2.2B-2.2D. In human intestinal fractions, no metabolites were detected at 
the early time points; however, at 2 h, a modest amount (16%) of the activity had been converted 
to the tetraethyl ester (C2E4) metabolite (Fig. 2.2B). The rapid disappearance of C2E5 in rat 
intestinal fractions coincided with time-dependent C2E4 formation as early as 10 min (Fig 2.2D). 
A minor amount of the triethyl ester (C2E3) was observed at later time points.  
C2E5 Hydrolysis Catalyzed by Human, Dog and Rat Liver S9 Fractions. As shown 
in Fig. 2.3A, C2E5 is rapidly metabolized in liver S9 fractions from all tested species. Human 
and dog S9 fractions hydrolyze approximately 85% of C2E5 within the first 30 min. No further 
metabolism was observed over the remainder of the 2 h incubation period. Similarly, rat S9 
fractions efficiently metabolized greater than 95% of C2E5 over the same incubation period. 
Interestingly, in all three species C2E5 hydrolysis correlated with primarily an increase in C2E4. 
In the case of human and dog fractions (Fig. 2.3B and 2.3C), C2E4 formation peaked at nearly 
80% of the detected activity by 60 min, before a slight decrease at the 120 min time point, due to 
minor increases in C2E3 and the diethyl ester (C2E2). In rat fractions, C2E4 formation was 
complete at 10 min and C2E3 became the predominant metabolite, accounting for nearly 80% of 
the detected activity, from 15 min through the duration of the assay (Fig. 2.3D). 
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C2E5 Hydrolysis Catalyzed by Human, Dog and Rat Plasma. Species differences are 
clearly evident when C2E5 was incubated in plasma of human, dog and rat (Fig. 2.4A). 
Moderate (~30%) and no C2E5 hydrolysis were observed in human and dog plasma respectively 
(Fig. 2.4A). Human plasma generated only C2E4 as a metabolite after 2 h of incubation, 
comprising approximately 30% of the total activity, while dog plasma did not show any 
detectable metabolites within this time period (Fig. 2.4B and 2.4C). In contrast, C2E5 was 
rapidly hydrolyzed in rat plasma and yielded a strikingly different metabolic profile, in which 
C2E4 was the primary metabolite in the first min of incubation (Fig. 2.4D and 2.4E). The 
principle metabolite identified within the first 60 min was C2E3 which accounted for ~60% of 
the activity. At the 2 h time point, there are equivalent amounts of C2E3, C2E2 and the mono-
ethyl ester (C2E1) each accounting for ~30% of the activity. The remaining activity was 
attributed to C2E4 and DTPA (Fig. 2.4E). 
C2E5 Hydrolysis Catalyzed by Recombinant Human CES1-b, CES1-c and CES2. 
Incubation of 1µM [14C]-C2E5 with human CES1 or CES2 supersomes are presented in Figure 
2.5. These data show that C2E5 was hydrolyzed (~15%) over 60 min.  CES1-b, CES1-c and 
CES2 all contribute to the hydrolysis of C2E5.  
Inhibition Studies of C2E5 Metabolism. The inhibition effects of BNPP on C2E5 
metabolite formation were investigated (Fig. 2.6). In the presence of the esterase inhibitor BNPP, 
C2E5 metabolism was significantly reduced in recombinant human CES1-b and CES1-c and 
human liver S9 fractions. 
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2.4 Discussion 
The path to FDA approval for treatments against bio- and nuclear-terrorism agents is 
unique. Instead of relying on human studies, the FDA Animal Rule allows approval of drugs that 
have been shown to be effective in animal models in the absence of clinical trials. However, the 
predictive human efficacy obtained in experimental animals is confounded by interspecies 
variations in metabolism. The inhibition effects of the specific esterase inhibitor, BNPP, 
confirmed that C2E5 was mainly cleaved by esterase. Our results provide direct evidence that 
C2E5 is metabolized in a species and tissue dependent manner. Additionally, C2E5 metabolism 
observed in the presence of recombinant human CES isoforms (CES1-b, CES1-c and CES2) 
further supports the role of the CES enzyme system in C2E5 hydrolysis. The current study 
suggests that the dog maybe the best for modeling human C2E5 exposure whereas the rat is 
uniquely useful for clarifying relative capacity of C2E5 to form more metabolites.  
Intestinal metabolism plays an important role in the bioavailability of oral therapeutic 
ester prodrugs. The expression of intestinal CES is species-dependent. For example, the small 
intestine contains only enzymes from the CES2 family in humans and rats whereas CES2 
expression is lacking in dog13. Consistent with the CES expression profile, C2E5 hydrolysis was 
absent following incubation in dog intestinal S9 fractions. However, C2E5 hydrolysis was 
minimal in human intestinal fractions whereas rat intestinal fractions almost completely 
hydrolyze C2E5 (Fig. 2.2B and 2.2D). The differing rates of metabolism observed in human and 
rat intestinal fractions may be explained, in part, by differential CES isoform expression. 
Humans express only one CES2 isoform, however, rats express one major CES2 (RL4) and four 
minor CESs in the intestine 19. In addition to differing CES expression, it has been shown that 
the intestinal CES2 of rat is markedly more efficient at metabolizing ester-containing compounds 
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than the human CES213 implying the rapid disappearance of C2E5 in rat intestinal fractions is 
due to the greater ability to hydrolyze C2E513. However, additional unidentified enzymes may be 
responsible for the distinct C2E5 metabolic profile identified in rat. Interestingly, in both human 
and rat intestinal S9 studies, C2E4 was the major metabolite. This may be due to the structure-
activity relationship between C2E5 and CESs.  Together, these results suggest that the intestine 
plays an important role in the CES-mediated first-pass metabolism of C2E5 in rats, but not in the 
dog and only to a small degree in human.  
CES1 and CES2 are all expressed abundantly in human, dog, and rat liver 20. The degree 
of C2E5 hydrolysis and the resultant metabolic profiles are vastly different between human and 
dog liver S9 fractions compared to rats. This could be due to different CES expression patterns in 
rats. The rat liver CES1 family includes 4 different isozymes, hydrolase A, hydrolase B, 
hydrolase C and rat egasyn and three minor CES2 isozymes (RL4, AY034877 and D50580). 
Among them, hydrolase A is the closest to the major human CES1 with about 78% homology 21. 
Observed species-dependent CES expression profile is probably responsible for the differences 
in the metabolism of C2E5 identified in human and dog when compared to rat. However, a direct 
comparison of the full complement of human, dog and rat CES isozymes would be needed to 
confirm these hypotheses. 
The formation of DTPA from C2E5 mediated by CES, and possibly other enzymes, 
appears to occur through four intermediates (C2E4, C2E3, C2E2, C2E1) as shown in Figure 1. 
C2E5 hydrolysis in S9 fractions suggests CES activities in the intestine and livers are insufficient 
for complete conversion to DTPA (Figs. 2.2 and 2.3). Thus, once C2E5, or a resulting 
metabolite, enters the systemic circulation, it is still susceptible to further metabolism by 
esterases present in plasma. Human and dog plasma have little or no detectable CES enzyme 15. 
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However, in human plasma there was a moderate level of C2E5 hydrolysis even in the absence 
of CES activity (Fig 2.4A and 2.4B). In contrast to human liver and small intestine where greater 
than 90% of esterase activity is attributed to CESs 22, butyrylcholinesterase (BuChE), 
paraoxonase (PON), and albumin esterase, but not CESs, possess hydrolytic activity in human 
plasma 15. Of the three PON isoforms (PON1, PON2, PON3), only PON 1 has hydrolytic activity 
23. Moreover, PON1 substrate specificity is restricted to organophosphate pesticides and nerve 
gasses 24,25, thus limiting the role that PON1 may play in the hydrolysis of C2E5. BuChE and 
albumin esterase, both of which contribute to the activation of prodrugs 26-29 are both likely to 
contribute to the hydrolysis of C2E5 in human plasma.  The fact that C2E5 was rapidly 
hydrolyzed in rat plasma is consistent with the presence of relatively high levels of CES activity 
in rat plasma. This represented the most efficient cleavage of the esters resulting in the time-
dependent formation of multiple metabolites.  
C2E5, a lipophilic compound with a CLogP value of 4.7, was hydrolyzed by recombinant 
protein CES1 and CES2 7. Hydrolysis of C2E5 by CES1 was higher than CES2 at an enzyme 
concentration of 1mg/ml (Fig. 2.5). The difference in activity is most likely due to the structural 
and conformational differences between CES1 and CES2. Human CES2 has been shown to have 
a greater affinity for lipophilic substrates compared to human CES1, possibly due to greater 
conformational flexibility and a larger entrance to the active site 28, but human CES1 prefers 
substrates with smaller alcohol groups. C2E5, a lipophilic molecule with small alcohol groups, 
possesses attributes that make it suitable for metabolism by both enzymes. However, the 
metabolites of C2E5 might be expected to have an increasing preference for CES1 because of the 
decrease in lipophilicity associated with the cleaving each ester. Any difference in metabolism 
between CES1-b and CES1-c is small because the enzymes are structurally very similar. In 
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contrast, CES1 and CES2 share only 48% of sequence homology 31. Bis-(4-nitrophenyl) 
phosphate (BNPP), an inhibitor of CES-mediated hydrolysis 32, inhibited C2E5 hydrolysis when 
added to samples of CES1-b, CES1-c, and human liver S9 (Fig 2.6). This result confirms that 
human recombinant proteins CESs are responsible for the hydrolysis of C2E5. Even though the 
inhibition is not one hundred percent, in all cases these results are consistent with the findings in 
literature on ester-based prodrug studies 32.  
During the development of pharmaceutical products, drug disposition and toxicity are 
usually evaluated in several different animal species. For a drug such as C2E5, the FDA Animal 
Rule requires an in depth understanding of differences in metabolic capacities among species. In 
conclusion, we have shown that C2E5 metabolism is species specific due to differing CESs 
expression profiles. Together, the results suggest that the dog is a better predictive model for 
C2E5 metabolism in humans whereas the rat is important for understanding the potential toxicity 
of C2E5 metabolites.  
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Figure 2.1. Proposed carboxylesterase-mediated metabolism of C2E5 to DPTA through 
four intermediates. 
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Figure 2.2. C2E5 Hydrolysis by Human, Dog, and Sprague-Dawley Rat Intestinal S9 
Fractions Fifty µM [14C]-C2E5 was pre-incubated in 0.1 M phosphate buffer (pH 7.4) for 5 min 
at 37°C. Reactions were initiated by the addition of intestinal S9 fractions (1 mg/ml final 
concentration) and were incubated at 37°C. The reactions were terminated at the indicated time 
points by addition of an equal volume of cold acetonitrile followed by centrifugation at 14,000 x 
g for 10 min at 4°C. The percent (A) C2E5 remaining and (B) human, (C) dog and (D) rat 
metabolic profiles [C2E4 (♦); C2E3 (○); C2E2 (▲); C2E1 (□); DTPA (●)] were determined by 
radio-HPLC. All assays were performed in triplicate and are expressed as the mean ± S.D.  
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Figure 2.3. C2E5 Hydrolysis by Human, Dog, and Sprague-Dawley Rat Hepatic S9 
Fractions. Fifty µM [14C]-C2E5 was pre-incubated in 0.1 M phosphate buffer (pH 7.4) for 5 min 
at 37°C. Reactions were initiated by the addition of hepatic S9 fractions (1 mg/ml final 
concentration) and were incubated at 37°C. The reactions were terminated at the indicated time 
points by addition of an equal volume of cold acetonitrile followed by centrifugation at 14,000 x 
g for 10 min at 4°C. The percent (A) C2E5 remaining and (B) human, (C) dog and (D) rat 
metabolic profiles [C2E4 (♦); C2E3 (○); C2E2 (▲); C2E1 (□); DTPA (●)] were determined by 
radio-HPLC. All assays were performed in triplicate and are expressed as the mean ± S.D. 
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Figure 2.4. C2E5 Hydrolysis by Human, Dog, Sprague-Dawley Rat Plasma Fractions. Fifty 
µM [14C]-C2E5 was added directly to plasma (pre-warmed for 5 min at 37°C). The reactions 
were terminated at the indicated time points by addition of an equal volume of cold acetonitrile 
followed by centrifugation (2X) at 14,000 x g for 10 min at 4°C. The percent (A) C2E5 
remaining and (B) human, (C) dog and (D, E) rat metabolic profiles [C2E4 (♦); C2E3 (○); C2E2 
(▲); C2E1 (□); DTPA (●)] were determined by radio-HPLC. All assays were performed in 
triplicate and were expressed as the mean ± S.D. 
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Figure 2.5. C2E5 Hydrolysis by CES1-b, CES1-c and CES2 One µM [14C]-C2E5 was pre-
incubated in 0.1 M phosphate buffer (pH 7.4) for 5 min at 37°C. Reactions were initiated by the 
addition of recombinant supersomes (1 mg/ml final concentration) and were incubated at 37°C. 
The reactions were terminated at the indicated time points by addition of an equal volume of cold 
acetonitrile followed by centrifugation at 14,000 x g for 10 min at 4°C. The disappearance of 
C2E5 was determined by radio-HPLC.  
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Figure 2.6. Inhibition Studies on C2E5 Hydrolysis. Fifty µM [14C]-C2E5 was pre-incubated in 
0.1 M phosphate buffer (pH 7.4) for 15 min at 37°C with addition of 100 uM BNPP. Reactions 
were initiated by the addition of recombinant supersomes (1 mg/ml final concentration) and were 
incubated at 37°C. The reactions were terminated at the indicated time points by addition of an 
equal volume of cold acetonitrile followed by centrifugation at 14,000 x g for 10 min at 4°C. The 
disappearance of C2E5 was determined by radio-HPLC.  
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CHAPTER 3 
BIOTRANSFORMATION CAPACITY OF CARBOXYLESTERASE IN SKIN AND 
KERATINOCYTES FOR THE PENTA-ETHYL ESTER PRODRUG OF DTPA 
 
3.1 Introduction 
	  
Transdermal drug delivery is non-invasive, can be self-administered, avoids first-pass 
metabolism, and is well suited to pediatric populations and specialized patient groups who have 
trouble swallowing 1. In addition, transdermal products are attractive due to their sustained zero-
order systemic release profile  2. However, to reach the systemic circulation, drug molecules need 
to pass through the skin’s multiple barriers including the hydrophobic environment of the 
stratum corneum, the epidermis and the dermis to reach the vascularized hypodermis. These 
barriers effectively limit direct transdermal drug delivery to molecules that possess aqueous 
solubility in physiological pH (> 1 mg/ml, pH 5-9), a low molecular weight (usually <500 
Daltons), moderate lipophilicity (oil-water partition coefficient Ko/w 10 – 1000), and those that 
require a moderate daily dosage (< 10 mg/day)  2, 3. A growing number of drugs, that have many 
of the properties listed above, have been approved for transdermal delivery.  These include 
estradiol, fentanyl, lidocaine and testosterone patches and ultrasonic delivery systems for 
analgesia  4, 5. 
In addition to the physical barriers, cutaneous metabolism via local phase I and phase II 
metabolic enzymes can also reduce bioavailability  6, 7. Cytochrome P450 enzymes are clearly 
expressed in organotypic skin models  8, 9.  In human skin, CYP families 1, 2 and 3 are 
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responsible for the metabolism of the majority of drugs and other xenobiotics  10. 
Xenobiotic metabolizing enzymes are located in the epidermis and dermis where hair follicles 
and sebaceous and sweat glands are located  11, 12. The study of dermal metabolism is 
complicated by significant interspecies differences in xenobiotic metabolism  13-15. Therefore, 
ideally, metabolism should be investigated in human skin tissue. 
Enzymatic metabolism in the skin can be utilized to bio-activate prodrug molecules and to 
improve dermal or transdermal delivery.  For example, morphine propionate and morphine 
enanthate are two alkyl ester prodrugs of morphine that have been shown to enhance dermal 
delivery of morphine by 2 and 5 fold, respectively  16. Many prodrugs, including these two 
morphine prodrugs, are formed by esterification of the active molecule. The added ester moiety 
can be used to alter the physicochemical properties of the molecule and improve transdermal 
absorption  16. Once absorbed into the skin, enzymatic hydrolysis of the prodrug by esterases 
releases the active drug. 
Carboxylesterases (CES1 and CES2) are involved in the metabolism of xenobiotics. For 
example, CES1 activates prodrugs of angiotensin-converting enzyme inhibitors and CES2 
activates the anticancer prodrug CPT-11 17, 18. In humans, CES1 and CES2 expression is 
ubiquitous; however, CES1 predominates in most organs  19. Although CESs are known to be 
expressed in human skin, information on their role in the metabolism of topically applied drugs 
and prodrugs is limited  20. 
We have developed a pentaethyl ester prodrug of the chelating agent diethylene triamine 
pentaacetic acid (DTPA), referred to as C2E5 (Fig. 1), to enhance clearance (decorporation) of 
transuranic radionuclides  21. C2E5 is metabolized by CESs  15 and the physiochemical properties 
of C2E5 (CLogP of 4.7, with a molecular weight of 533 Daltons) suggest that it would be a good 
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candidate for transdermal delivery. Evidence supporting transdermal application of C2E5 was 
reported in rat in vivo transdermal pharmacokinetics and efficacy studies  21. Therefore, the first 
objective of the current work was to assess the expression of CES isoforms in four different 
human skin cell lines. The second objective was to determine the capacity of the CESs in each 
cell line to metabolize the prodrug C2E5. 
3.2 Materials and methods 
	  
Materials. [14C]-DTPA penta-ethyl ester ([14C]-C2E5; 55 mCi/mmol, 1mCi/ml) was 
purchased from American Radiolabeled Chemicals, Inc. (St. Louis, MO). Ultima-Flo AP 
scintillation fluid was obtained from PerkinElmer Life and Analytical Sciences (Waltham, MA). 
Acetonitrile (ACN), 4-nitrophenyl valerate (4-NPV), p-nitrophenyl acetate (PNPA), Dulbecco’s 
modified Eagle’s medium, 0.25% trypsin-EDTA, and Dulbecco’s phosphate buffered saline 
(PBS) were purchased from Sigma Aldrich (St. Louis, MO).  Penicillin-streptomycin was 
purchased from Invitrogen Corporation (Carlsbad, CA). Fetal bovine serum was purchased from 
Cansera International Inc. (Rexdale, ON, Canada). Human Female skin S9 fractions were 
purchased from BioreclamationIVT (Hicksville, NY). 
Cell Culture. HaCaT cells, immortal human keratinocytes, and A431, an immortalized 
epidermoid carcinoma derived, were kindly provided by Dr. Zhi Liu (Lineberger Comprehensive 
Cancer Center, Chapel Hill, NC). Primary neonatal human epithelial kerotinocytes (HEKn) and 
adult human epithelial kerotinocytes (HEKa) cells were obtained commercially (Gibco by Life 
Technologies, Grand Island, NY). HaCaT and A431 were maintained in 10% fetal bovine serum 
and Dulbecco’s modified eagle medium/high glucose medium (Gibco) containing 10% fetal calf 
serum, penicillin (10,000 units/ml) and streptomycin (10 mg/ml) until sub-confluence was 
reached (after 48 h). HEKn and HEKa were cultured in EpiLife medium (Gibco), supplemented 
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with 1% EpiLife® defined growth supplement and 0.1% calcium chloride (CaC12) (Gibco). All 
incubations were conducted at 37±1°C, 95% air/5% CO2, and saturated humidity. 
Preparation of Cell Supernatant (S9 fractions). For all cell lines, cytosolic S9 fractions 
were prepared as cited in literature (Imai et al.,  2013). Protein concentrations were determined 
by the PierceTM BCA protein assay (Thermo Fisher Scientific, Waltham, MA).  Human liver S9 
fractions (XenoTech, Kansas City, KS), human recombinant protein (BD Biosciences, Franklin 
Lakes, New Jersey), and human skin S9 fractions (BioreclamationIVT, Hicksville, NY) were 
purchased commercially. 
Determination of the Genetic Expression by real time reverse transcription-
polymerase chain reaction (RT-qPCR).  HEKa, HEKn, HaCaT and A431 cells were seeded 
and grown in 15 ml in T75 tissue culture flasks. Expression of the CESs genes were evaluated by 
RT-qPCR. Total RNA was extracted using the RNeasy Mini Kit (Qiagen, Cat. No.74134, 
Hilden, Germany) according to the manufacturer’s instructions. Briefly, cell samples were lysed 
and homogenized using 1ml/10cm2 cells of  TRIzol (Ambion® by Life Technology) and then 
were isolated by QIAshredder columns (Qiagen Cat. No.79656) in a highly denaturing 
guanidine-thiocyanate containing buffer.  Ethanol (70%) was added and the samples were 
applied to an RNeasy Mini Spin Column (Qiagen). RNA was bound to the membrane of the 
column and contaminants were washed away. Subsequently, RNA was eluted from the column 
using 30 µl of water.  The concentration and purity of the total RNA was determined using the 
Nanodrop 2000 method (Thermo Scientific,Wilmington, DE). cDNAs were prepared by reverse 
transcription of total RNA using the iScriptTM cDNA synthesis kit (Bio-Rad cat #170-8891, 
Hercules, CA) and stored at -20ºC until qPCR amplification.  qPCR reactions were prepared 
using the 2X iTaqTM Universal Probes Supermix, TaqMan® CES1, CES2 and glyceraldehyde-3-
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phosphate dehydrogenase (GAPDH) primers, (TaqMan® Gene Expression Assays Rack ID: 
14429192. Primers: Hs00275607_m1 for CES1, Hs01077945_m1 for CES2 and Hs02758991_g1 
for GAPDH) (Applied Biosystems, Foster City, CA) and nuclease-free water (Qiagen) cDNA 
was diluted 5-fold and qPCR was performed by the TaqMan® Gene Expression Assay (Bio-
Rad). The PCR amplification was conducted in a total volume of 20 µl containing universal PCR 
master mixture (10 µl), gene-specific TaqMan® assay mixture (1 µl), diluted cDNA (5 µl) and 
nuclease-free water (4 µl). The cycling profile was 50°C for 2 min, 95°C for 10 min, followed by 
40 cycles of 15 s at 95°C and 1 min at 60°C, as recommended by the manufacturer. 
Amplification and quantification were done with the Applied Biosystems 7900HT Real-Time 
PCR System (Foster City, CA). All samples were analyzed in triplicate and the signals were 
normalized to GAPDH and then expressed as relative levels of mRNA. The CES1 probe 
recognized both CES1A1 and CES1A2; these enzymes are identical although distinct genes 
encoded. GAPDH was included in the study as the loading control. 
Quantification of Gene Expression. Relative RNA expression levels were determined 
from delta Ct values using the expression of the GAPDH gene as an internal control. The real-
time RT-qPCR assay was performed in triplicate for each sample. For each replicate, the CES Ct 
was normalized to the GAPDH Ct [ΔCt = Ct[Target]-Ct[Gapdh]] before the mean and SEM ΔCt was 
calculated. 
Determination of the Protein Expression. Western blot studies were conducted to 
explore CES1 and CES2 expression in the different human skin cell lines. CES1 and CES2 
antibodies were purchased from Abcam (Cambridge, England).  Protein concentrations were 
determined using the PierceTM BCA Protein Assay (Thermo Fisher Scientific). Total protein 
lysate (30 µg) was run on a NuPAGE™ 4–12% Bis-Tris Gel (Bio-Rad) at 120 V for 1 h.  
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Following electrophoresis, the proteins were transferred by blotting onto 0.45 µm polyvinyl 
difluoride membranes (Thermo Fisher Scientific) at 350 mA for 1.25 h in transfer buffer (Bio-
Rad). The membrane was blocked in 5% skimmed milk powder in Tris-buffered saline/0.05% 
Tween for 1 h before overnight incubation with primary antibody: monoclonal hCES1 or hCES2 
(Sigma-Aldrich) at 1:1000 dilution or GAPDH (Abcam) at 1:10,000 dilution. The membranes 
were washed and incubated with a secondary antibody, horseradish peroxidase-conjugated goat 
anti-rabbit (Sigma-Aldrich) at 1:10000 dilution for 1 h. Finally, the membranes were incubated 
briefly in SuperSignal® Stable Peroxide Solution together with SuperSignal® West Pico 
Luminol/Enhancer Solution (Thermo Fisher Scientific) and immediately imaged. The 
chemiluminescent signal was registered with a FluorChem 8000 camera (Alpha Innotech Corp, 
San. Leandro, CA).  Human liver and intestine S9 fractions served as positive controls for CES1 
and CES2, respectively.  
Determination of Enzyme Activity by PNPA Assay and 4-NPVAssay. Total esterase 
and CESs-specific enzyme activity was measured using established substrates PNPA (100µM) 
and 4-NPV (100µM), respectively. Hydrolysis of the freshly prepared substrates was carried out 
in 96 well plates with a total volume of 100 µl/well. Reactions were initiated by mixing 1 µl of 
substrate with diluted S9 samples (0.1 mg/ml). The rates of hydrolysis of PNPA and 4-NPV were 
determined spectrophotometrically by measuring reaction products at 402 nm after 10 min 
incubation at 37°C as previously described  22 using a UV spectrometer (BioTek, Winooski, VT). 
Analysis was performed using Microsoft Excel.  
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Determination of C2E5 Hydrolysis by High Performance Liquid Chromatography-
Radiomatic Flow Scintillation Analyzers (HPLC-FSA). [14C]-C2E5 (1 µM, 0.55 nCi) was 
pre-incubated in 0.1 M phosphate buffer (pH 7.4) for 5 min at 37°C. Reactions were initiated by 
the addition of S9 fractions (1 mg/ml) from different cell lines (HEKa, HEKn, HaCaT and A431) 
in a total volume of 100 µl; boiled S9 fractions were used as a blank to correct for non-enzymatic 
C2E5 degradation.  The reactions were terminated by adding an equal volume of ice-cold 
acetonitrile (ACN), followed by centrifugation at 14,000g for 15 min at 4°C. The supernatant 
was transferred to HPLC vials for analysis as previously described  15. Representative 
radiochromatograms shown in supplemental figures 1 and 2 illustrate a C2E5 peak generated 
from the boiled S9 fractions and C2E5 and the presences of a metabolite, C2E4, in human skin 
S9 fractions. 
Sample Preparation for Human Skin S9 fractions-Mediated C2E5 Hydrolysis with 
and without Inhibitors.  Experiments were designed to examine the effect of specific inhibitors 
on C2E5 hydrolysis in human skin S9 fractions.  The following inhibitors were selected: benzil 
(10 µM) was chosen as a pan CES inhibitor  23, troglitazone (10 µM) as a CES1 specific inhibitor  
24, loperamide (100 µM) as a CES2 specific inhibitor  25 and BNPP (1 mM) as a non-specific 
esterase inhibitor  26.  Inhibitors were incubated with human skin S9 fractions for 30 min at 37°C 
before the reaction was initiated. All reactions were initiated by the addition of S9 fractions (0.5 
and 1 mg/ml) to prepared C2E5 in water to result a final C2E5 concentration of 0.5 µM at 37°C. 
Reactions were terminated after 120 mins by adding an equal volume of ice-cold acetonitrile 
with 2% of formic acid, followed by centrifugation at 14,000 g for 15 min at 4°C. Liver S9 
fractions (1 mg/ml) were used as a positive control and boiled S9 fractions were used as negative 
controls. Reactions were performed in triplicate. The standards used to generate the LC/MS/MS 
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C2E5 calibration curve were prepared by spiking boiled S9 fractions with C2E5 and processed as 
described above. 
LC/MS/MS Chromatographic and Spectroscopic Conditions.  Chromatographic 
separation from matrix components was achieved using reverse-phase chromatography on an 
YMC ODS-AM C18 (100 x 2 mm, 3 µm) column.  Gradient elution was used based on a 
combination of water with 0.1% formic acid (A) and acetonitrile with 0.1% formic acid (B). The 
mobile phase was initiated at 13% B increasing to 40% B by 1 min, to 60% B by 6 min and to 
95% B by 6.2 min. The mobile phase was held at 5% A and 95% B from 6.2 min to 6.5 min 
when a post-run cycle that included isopropyl alcohol (C) was initiated. Between 6.5 min and 7 
min solvent B (95%) was gradually replaced with solvent C (95%). The mobile phase was then 
held at 5% A 95% C until 7.5 min before gradually returning to initial conditions (87% A, 13% 
B, 0% C) after 8.5 mins, which were maintained for 1.5 mins prior to the next injection. The 
flow rate was 300 µl/min and the injection volume was 5 µl. The column oven temperature was 
set to 40 °C. C2E5 was detected on a triplequadrupole mass spectrometer (Thermo TSQ 
Quantum Access) using electrospray ionization (ESI) in the positive-ion mode. The ionization 
source and collision parameters were optimized to give maximum analyte signal intensity (Spray 
Voltage 3500V; Sheath and Auxiliary gas nitrogen, 10 and 25 psi, respectively; Collision gas 
Argon @ 1.5 mTorr; Collision energy 35 eV). The mass spectrometer was set to carry out single 
reaction monitoring (SRM) for the precursor → product ion transitions m/z 534 → 216 (C2E5) 
and m/z 506 → 188 (C2E4) at a retention times of 3.6 and 2.8 min, respectively. For C2E5 
quantification, a calibration plot of analyte peak area against nominal C2E5 concentration (20 – 
1000 ng/mL) was constructed from a quadratic equation with a 1/concentration2 weighting. 
Representative chromatograms showed formation of C2E5 metabolite, C2E4. Representative 
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chromatograms shown in supplemental figures 3 and 4 illustrate a C2E5 peak generated from the 
boiled S9 fractions and C2E5 and the presences of a metabolite, C2E4, in human skin S9 
fractions. 
Data analysis. The data were processed by Graph Pad Prism 5.0, and are presented as 
mean ± SEM. 
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3.3 Results 
 
Genetic Expression of Carboxylesterase in HEKa, HEKn HaCaT, A431 cells, and 
Human Skin Tissue. The mRNA expression of CES1 was primarily detected in human skin 
tissue. A small amount was detected in HEKa and HEKn cells, and none was detected in HaCaT 
and A431 cells (Fig. 3.2A). In contrast, mRNA expression of CES2 was detected in all cells. 
Human skin CES2 expression was about 2-fold higher than HEKa, HEKn and HaCaT and 10-
fold higher than A431 expression (Fig. 3.2B). CES1 expression in the human skin was about 25-
fold greater than CES2 expression. However, the human skin total RNA was obtained from only 
one human subject and inter-individual variability could affect these comparative results. 
Protein Expression of Carboxylesterase in HEKa, HEKn, HaCaT, A431 cells and 
Human Skin Tissue. Human liver and intestine S9 fractions were used as positive controls. 
CES1 protein expression was detected in human skin S9 fractions.  The band for CES1 in human 
skin (30 µg of skin sample) was considerably lighter than the CES1 band in human liver S9 
fractions (5 µg of liver sample). There was little evidence of CES1 in HEKn, HaCaT and A431 
cells (Fig. 3.3A). Meanwhile, CES2 protein expression was detected in HEKn, HaCaT, human 
skin and human intestine S9 fractions (Fig. 3.3B). The bands indicated that more CES2 was 
present in HEKn compared to HaCaT. Little evidence for CES2 in A431 was observed (Fig. 
3.3B). 
Hydrolysis Activity of PNPA and 4-NPV in HEKa, HEKn, HaCaT, A431 cells and 
Human Skin Tissue. Enzymatic activity was determined using PNPA (esterases) and 4-NPV 
(CES) assays with human liver S9 fractions as a control. The PNPA assay demonstrated that the 
S9 fractions from human skin cell lines exhibited esterase activity (Fig. 3.4A). PNPA hydrolysis 
activity in the cultured cells was slightly lower than in human skin S9 fractions and 5- to 10-fold 
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lower than in human liver S9 fractions (Table 3.1). For example, HEKn displayed approximately 
20% of the esterase activity of the liver. When the amount of protein was standardized across all 
the samples, the catalytic rate of esterase in HEKn was the highest among all cell lines.  The 4-
NPV assay showed that CES activity was present in all of the tested cells; the catalytic rate of 
CES in HEKn cell lines was the greatest (Fig. 3.4B). 4-NPV hydrolysis activity in the cultured 
cells was comparable to or slightly lower than in human skin S9 fractions and 2- to 5-fold lower 
than in human liver S9 fractions (Table 3.2). For example, HEKn displayed approximately 60% 
of the CESs activity of the liver. 
Hydrolytic Activity of Penta-ethyl Ester Prodrug of DTPA (C2E5) in HEKa, HEKn, 
HaCaT A431 Cell Lines.   S9 fractions produced from HEKa, HEKn, HaCaT hydrolyzed [14C]-
C2E5 (1µM) to the primary metabolite, C2E4. Little hydrolysis was observed in the S9 fractions 
of A431 cells (Fig. 3.5A). The hydrolytic rates of C2E5 by HEKa, HEKn, HaCaT and A431 cells 
were 7.12, 2.63, 3.80 and 0.66 pmol/mg/min, respectively. 
Inhibition of Hydrolytic Activity of Penta-ethyl Ester Prodrug of DTPA (C2E5) in 
Human Skin S9 Fractions. Near complete (98.6%) hydrolysis was seen in human liver S9 
fractions, while human skin S9 fractions showed 62.8% loss of the parent drug (C2E5, Fig 3.6). 
As expected, addition of the non-specific esterase inhibitor, BNPP, totally blocked the hydrolysis 
of C2E5.  Addition of the inhibitors benzil (pan CESs) troglitazone (CES1) and loperamide 
(CES2) resulted in 10.6%, 40.68%, and 77.68% loss of parent drug C2E5, respectively. These 
data suggest that both CES1 and CES2 hydrolyze C2E5, but the hydrolysis is primarily via 
CES1. 
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3.4 Discussion 
	  
As transdermal delivery technology becomes more common, questions remain as to how 
and whether ester-based prodrugs pass through the skin and whether hydrolysis during this 
transition effects the absorption, distribution, metabolism and excretion (ADME) of the drug. 
Because of interspecies differences in hydrolysis profiles, skin derived from animals may be very 
different from human skin 14, 27, 28.  Therefore, alternative methods to examine human specific 
hydrolysis are needed during drug development. Previously, we reported that CESs play an 
important role in the metabolism of the ester-based prodrug, C2E5, which is being investigated 
as a decorporation agent for contamination with transuranic elements  21. The present study 
characterized CESs expression and activity in human skin tissue and different human 
keratinocyte cell lines and demonstrated the role of CESs in facilitating C2E5 hydrolysis in skin 
during transdermal delivery. In addition, the prodrug, C2E5, was hydrolyzed in all skin cell lines 
examined and that HEKa cells may be the most appropriate cell line to study its transdermal 
delivery. 
CES1 and CES2 proteins were expressed in human skin S9 fractions. RT-qPCR clearly 
showed greater expression of CES1 mRNA compared to CES2 mRNA, which supports a 
previous report of greater CES1 expression in human skin microsomes  29. As expected, 
measurement of total esterase activity using the PNPA assay  30 revealed much less activity in the 
skin compared to the liver (Fig. 3.4A). However, the 4-NPV assay, which measures CES activity  
25 showed that total CESs activity was only 2-fold lower in the skin than in the liver (Fig. 3.4B), 
confirming the potential for human skin to contribute to the metabolism of ester compounds 
when applied transdermally  16. 
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As an alternative to human skin, we assessed different human keratinocyte cell culture 
models for their utility as surrogates in investigating transdermal drug metabolism. The 
keratinocyte tumor cell line A431 had no detectable CES1, and CES2 was expressed at barely 
detectable levels. Therefore, we concluded that A431 cell line is not a suitable model for 
investigating transdermal drug metabolism. Of the remaining keratinocyte cultures, our results 
demonstrated that while HEKa, HEKn and HaCaT express CES1, CES2 was more abundant 
across the various keratinocyte cell lines. These findings are consistent with the work of Zhu et 
al. who identified CES2 as the main CES in HaCaT cells  20. Enzyme expression and activity in 
keratinocytes change over time in culture; cytochrome P450 enzymes are particularly vulnerable, 
but esterases and conjugated enzymes are also affected  22. This observation could explain our 
findings that CES2 expression was slightly lower in HaCaT cells compared to HEKa or HEKn 
cells, and that CES1 expression was greatly reduced or absent in all the cultured cells. HEKa and 
HEKn are primary cultures and, as such, may retain the greater enzymatic activity observed in 
human skin compared to the immortalized HaCaT cell line. 
CES1 and CES2 are from the same family, known as 60-kDa serine esterase. While these 
two isoforms have a similar molecular weight, (CES1 is 62.5 KDa and CES2 is 60.0 KDa), they 
are structurally quite different.  The isoelectric point of CES1 is 5.8 and CES2 is 4.9 and the 
sequence homology between the two enzymes is only 48%  31. These structural differences result 
in different substrate specificity. CES1 tends to hydrolyze molecules with a small alcohol moiety 
more efficiently, while CES2 is more efficient at metabolizing molecules with a larger alcohol 
moiety and more lipophilic molecules  25, 32. These differences in the substrate specificity of 
CES1 and CES2 could lead to differences in predicting skin absorption or metabolism. In 
different human cell lines and skin S9 fractions, we demonstrated CESs expression by western 
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blot and RT-qPCR and confirmed activity with PNPA and 4-NPV assays; subsequently, we 
examined the metabolism of C2E5, a prodrug developed for transdermal delivery. 
C2E5 is the penta-ethyl ester of DTPA, administered intravenously to treat plutonium, 
americium, and curium (Pu, Am and Cm) contamination. In vivo studies, in rats, report de-
esterification of C2E5 mainly into the tri- and di-ethyl esters, C2E3 and C2E2, with some DTPA 
also present  21. In vitro binding experiments, using human, rat and dog plasma, suggest that 
C2E2 is an effective chelator of Am  33, and this hypothesis is supported by efficacy study 
following oral administration of C2E2 in beagle dogs  34. Thus, to be effective, when applied 
transdermally, C2E5 needs to be metabolized to C2E2 in the body. Sustained plasma 
concentrations of C2E2 are observed in rats following transdermal application of C2E5 in a non-
aqueous gel  21 and this is associated with effective Am decorporation  35, suggesting that 
transdermal delivery of C2E5 to the active C2E2 is possible. In the present study, we used the S9 
fractions model to assess the potential translation of these preclinical observations to human 
tissues. 
Previously, we used a human recombinant protein system to examine human CES1 and 
CES2 mediated C2E5 hydrolysis; the results demonstrated that  both CES1 and CES2 were 
reponsible for C2E5 hydrolysis. However, CES1 hydrolyzed C2E5 to a greater extent compared 
to CES2  15. The results in the current study agree with our previous findings (Fig. 3.5 and 3.6). 
Although complete metabolism to an active drug, C2E2, was not observed in human skin in the 
current study, once in the systemic circulation, further hydrolysis of C2E5’s metabolites can 
occur in the liver, mainly by CES 1, and in plasma, possibly by paraoxonase and 
butrylcholinesterase as CES1 and 2 are not present  36. Additionally, the metabolism of C2E5 by 
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CESs in keratinocytes, which we report here, results in metabolites that are more hydrophilic 
than C2E5 and could potentially more readily enter the systemic circulation. 
The differences in enzyme activity and expression among cell lines and skin tissue has important 
implications for future studies examining transdermal metabolism of ester-based prodrugs. 
HEKa, HEKn and HaCaT cell cultures have the potential for examining the metabolism of 
compounds that are substrates for CES2. However, of the human cell lines we examined, only 
HEKa cells have the potential for establishing the metabolism of compounds that are substrates 
for CES1. 
In summary, this is the first study to characterize the expression of CES isoforms in 
multiple human skin cell lines and human skin tissue with a view to using native phase 1 
enzymes in skin to enhance transdermal delivery of C2E5. The differences in enzyme activity 
and expression among cell lines and skin tissue has important implications for future studies 
examining transdermal metabolism of ester-based prodrugs. We confirmed that CES activity is 
present in skin, albeit at lower levels compared to the liver, and that CES2 activity, but not CES1 
activity, in HEKa, HEKn and HaCaT cells is comparable to that of human skin. Consequently, 
human skin cell cultures may be useful in quantifying CES2-mediated drug metabolism. Of the 
human cell lines we examined, HEKa cells have the potential for establishing the metabolism of 
compounds that are substrates for CES1. However, caution should be used when human skin 
cells lines are used as alternative models for human cutaneous metabolism in transdermal drug 
delivery. Since the CES1 specific inhibitor reduced human skin S9 fractions-mediated hydrolysis 
of C2E5, CES1 appears to be crucial for C2E5 metabolism; as a result, the HEKa cell line could 
be an appropriate model for metabolism of C2E5. 
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Table 3.1. Esterase activity in human skin cell cultures, human skin S9 fractions and 
human liver S9 fractions 
Cell Type  Hydrolytic 
activity 
(nmol/min/mg) 
HEKa 20.2 ± 1.82 
HEKn  31.6 ± 3.76 
HaCaT 26.2 ± 1.97 
A431  16.7 ± 1.11 
Human skin  39.0 ± 11.54 
Human Liver  167.2 ± 5.50 
   Data are the Mean ± SEM. N = 3. 
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Table 3.2. Carboxylesterase activity in human skin cell cultures, human skin S9 fractions 
and human liver S9 fractions  
Cell Type  Hydrolytic 
activity 
(nmol/min/mg) 
HEKa 40.9 ± 8.87 
HEKn  125.8 ± 5.87 
HaCaT 103.0 ± 9.65 
A431  57.3 ± 7.56 
Human skin  114.3 ± 5.60 
Human Liver  217.7 ± 13.83 
  Data are the Mean ± SEM. N = 3. 
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Figure 3.1. Structure of penta-ethyl ester DTPA prodrug (C2E5). 14C-radiolabel positions are 
indicated by asterisks.  
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Figure 3.2. Log of relative expression of CES1 and CES2 mRNA in human epidermal 
keratinocyte HEKa, HEKn, HaCaT, A431 cells and human skin by RT-qPCR analysis. [A] CES1 
expression. [B] CES2 expression. Values represent mean ± SEM (n=3).  
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Figure 3.3. Western blot analysis of human epidermal keratinocyte HEKn, HaCaT and A431 
cells and human tissue. Each band was detected with CES1 and CES2 antibodies. [A] CES1 
expression. [B] CES2 expression. Lane 1 = HEKn, 2 = HaCaT, 3 = A431, 4 = human skin, 5A = 
human liver, and 5B = human intestine.  
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Figure 3.4. Esterase and carboxylesterase activities in human epidermal keratinocyte HEKa, 
HEKn, HaCaT, A431 cells and human skin tissue measured with a PNPA and 4-NPV assay. [A] 
PNPA assay in the presence of S9 fractions of HEKa, HEKn, HaCaT, A431 cells and human 
skin. [B] 4-NPV assay in the presence of S9 fractions of HEKa, HEKn, HaCaT, A431 cells and 
human skin. The hydrolysis of the freshly prepared substrates was carried out in 96 well plates 
with a total volume of 100 µl/well. Reactions were initiated by mixing 1 µl of substrate with 
diluted S9 samples (0.1 mg/ml). The rates of hydrolysis of PNPA and 4-NPV were determined 
spectrophotometrically by measuring reaction products at 402 nm after 10 min incubation at 
37°C using a UV spectrometer. Values represent mean ± SEM. (n=3). 
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Figure 3.5. C2E5 hydrolysis in human epidermal keratinocyte HEKa, HEKn, HaCaT, A431 cells. 
Loss of parent drug was measured by detecting changes in radioactivity of C2E5 at HPLC 
elution peak (7.3 min) during a 60 mins incubation of 1µM [14C]-C2E5 with HEKa, HEKn, 
HaCaT and A431 cells. Values represent mean ± SEM (n=3). 
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Figure 3.6. C2E5 hydrolysis in human skin S9 fractions and inhibition studies on C2E5 
hydrolysis. Inhibitors, benzil, trogliazone, loperamide, and BNPP were incubated with human 
skin S9 fractions for 30 min at 37°C before the reaction was initiated. Loss of parent drug was 
measured by detecting changes in spectromatogram at the LC/MS/MS analyte peak (3.6 min) 
after 120 mins incubation of 0.5 µM C2E5 with human skin S9 fractions with and without 
inhibitors. Liver S9 fractions (1 mg/ml) were used as a positive control and boiled S9 fractions 
were used as negative controls. Values represent mean ± SEM (n=3). 
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CHAPTER 4 
THE EFFECT OF EXCIPIENTS ON CARBOXYLESTERASE-MEDIATED HYDROLYSIS 
OF A DTPA PRODRUG FOR TRANSDERMAL DELIVERY 
4.1 Introduction  
	  
Pharmaceutical excipients are substances that preserve and support active drugs to retain 
their optimal biopharmaceutical activities during treatment. Excipients can serve in a variety of 
ways, including as manufacturing aids, stability enhancing agents and as coloring, taste masking 
and coating agents. Traditionally, excipients are inactive, exerting no effect on active drugs. 
However, an increasing number of reports have demonstrated that some excipient affect the 
ADME properties of active drug or increase the potential for patients to develop toxicities at 
higher excipient doses. For instance, Tween 80, an excipient in some amiodarone formulations, 
has been reported to cause hepatotoxicity and reduce the level of phase II metabolic enzyme, 
glutathione S-transferases 1. Hydroxypropyl-beta-cyclodextrin causes transaminase to increase in 
rodents 2 . High doses of propylene glycol have been reported to cause cardiovascular 
abnormalities, renal failure and CNS changes 3.  Solubilizing agents appear to alter intestinal 
membrane barrier functions and cause damage to the intestinal epithelium, for example, sodium 
taurocholate (NaTC), Gelucire 44/14 and Cremophor EL 4. Meanwhile, there is an increased 
interest in evaluating the effect of excipients on metabolic enzymes and drug transporters. 
Labrasol at low concentrations inhibits the function of the efflux transporter P-gp in the intestine 
and thus increases the intestinal absorption of P-gp substrates 5. Polyethylene glycol (PEG) 400, 
HP-beta-CD, Solutol HS 15  (SOL), and Cremophor EL (EL 35) alter OATP biopharmaceutical 
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functionality 6.  Polyoxyl 35 castor oil, Tween 80, PEG400, and EL 35 can affect the activity of 
cytochrome P450 enzymes 7. 
Interest in the development of transdermal drug delivery has been increasing because it is 
non-invasive, can be self-administered, avoids first-pass metabolism, and is well suited to special 
populations. Many drugs that are delivered via transdermal and topical routes require a specific 
category of excipients due to the unique anatomical structure of skin.  Generally, excipients used 
in transdermal delivery are non-ionic or oil-based in order to make them easily miscible with 
formulations containing active pharmaceutical ingredients with oil/water partition coefficients 
between 10 and 1000. Excipients found in transdermal formulations include sodium dodecyl 
sulfate (SDS), Tweens, Spans, polyethylene glycol, povidone and others. Ester-based and amide-
based drugs delivered by transdermal route are designed to be metabolized to the active drug by 
CESs, which are ubiquitous Phase I metabolic enzymes. CESs play a vital role in determining 
the metabolic paths for both xenobiotic and endogenous compounds.  Currently, little is known 
about the effect of excipients used in transdermal delivery formulation on the activities of CESs 
in human.  
We have developed a penta-ethyl ester prodrug of the chelating agent diethylene triamine 
penta-acetic acid (DTPA), referred to as C2E5 (Fig. 1), to enhance decorporation of transuranic 
radionuclides 8. C2E5 is metabolized by CESs 9 and the physiochemical properties of C2E5 
(CLogP of 4.7, 533 Da) suggest that it would be a good candidate for transdermal delivery. 
Evidence supporting transdermal application of C2E5 was reported in in vivo transdermal 
pharmacokinetics and efficacy studies 8.  Therefore, the objective of current work is to assess the 
effect of common excipients, on skin CES-mediated hydrolysis of C2E5.  
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Table 4.1. List of 12 excipients used in transdermal delivery.  
 Application  Name  
1 Nonaqueous gel for the 
transdermal delivery of a DTPA penta-ethyl 
ester prodrug 10 
Mi   Miglyol 840 
2 The effect of Miglyol 812 oil on the oral 
absorption of propranolol in the rat 11 
 
Miglyol 812 
3 Transdermal delivery of propranolol using 
mixed grades of Eudragit: design and in 
vitro and in vivo evaluation 12  
Eudragit RL PO 
4 Eudragit RS PO 
5 Effect of ethanolamine salts and enhancers 
on the percutaneous absorption of 
piroxicam from a pressure sensitive 
adhesive matrix74  
Crodamol EO-LQ-(MH) 
6 Formulation and evaluation of 
microemulsion system for transdermal 
delivery of nimodipine 13 
Capmul MCM 
7 Ultra-fine self nanoemulsifying drug 
delivery system for transdermal delivery of 
meloxicam: dependency on the type of 
surfactants 14 
Capmul MCM EP 
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8 Novel nanoemulsion as vehicles for 
transdermal delivery of clozapine: in vitro 
and in vivo studies 15 
Captex 355 
9  Development of a microemulsion 
formulation for antimicrobial SecA 
inhibitors 16  
Polyoxyethylene tridecyl ether 
10  Effect of surfactants on the characteristics 
of fluconazole niosomes for enhanced 
cutaneous delivery 17  
Brij 72 
11 The effect of excipients on the permeability 
of BCS Class III compounds and 
implications for biowaivers 18 
 
Sodium lauryl sulfate (SLS) 
12  Status of surfactants as penetration 
enhancers in transdermal drug delivery 19 
 
Tween 20 
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4.2 Materials and Methods 
Chemicals Diethylenetriaminepentaacetic acid pentaethyl ester (C2E5) was prepared 
using the Fischer esterification method by reacting DTPA with ethanol under reflux in the 
presence of a hydrochloric acid catalyst 20 Human skin S9 fractions were purchased from Celsis 
In Vitro Technologies (Baltimore, MD). Human liver S9 fractions were purchased from 
Xenotech LLC (Lenexa, KS). Absolute ethanol and acetonitrile were purchased from Acros 
Organics (NJ). Miglyol 840 and 812, (Sasol, Hamburg, Germany), Eudragit RL PO and Eudragit 
RS PO ( Evonik-Degussa GmbH, Darmstadt, Germany), Crodamol EO-LQ-(MH) (Croda Inc, 
Edison, NJ), Capmul MCM, Capmul MCM EP, Captex 355(Abitec Corporation, Columbus, 
Ohio, US), Polyoxyethylene tridecyl ether  (Sigma-Aldrich, St. Louis, Missouri),  SLS (Fisher 
scientific, NJ) and Tween 20 (Sigma-Aldrich, St. Louis, Missouri) were purchased. 
 Sample Preparation for Human Skin S9 fractions-Mediated C2E5 Hydrolysis with 
and without excipients.  Experiments were designed to examine the effect of excipients on 
C2E5 hydrolysis in human skin S9 fractions.  The excipients analyzed are listed in the Table1. 
Excipients at various concentrations (0, 0.1, 1, 10 and 100 µg/ml) were incubated with human 
skin S9 fractions for 30 min at 37°C before the reaction was initiated. All reactions were initiated 
by the addition of S9 fractions (0.5 and 1 mg/ml) to prepared aqueous solutions of C2E5 with a 
final C2E5 concentration of 0.5 µM at 37°C. Reactions were terminated after 120 min by adding 
an equal volume of ice-cold acetonitrile with 2% of formic acid, followed by centrifugation at 
14,000 g for 15 min at 4°C. Liver S9 fractions (1 mg/ml) were used as a positive control; boiled 
S9 fractions were used as negative controls. All reactions were performed in triplicate. The 
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standards used to generate the LC/MS/MS C2E5 calibration curve were prepared by spiking 
boiled S9 fractions with C2E5 and processing as described above.  
 
LC/MS/MS Chromatographic and Spectroscopic Conditions. Chromatographic 
separation from matrix components was achieved using reverse-phase chromatography on an 
YMC ODS-AM C18 (100 x 2 mm, 3 µm) column.  Gradient elution was used based on a 
combination of water with 0.1% formic acid (A) and acetonitrile with 0.1% formic acid (B). The 
mobile phase was initiated at 13% B increasing to 40% B by 1 min, to 60% B by 6 min and to 
95% B by 6.2 min. The mobile phase was held at 5% A and 95% B from 6.2 min to 6.5 min 
when a post-run cycle that included isopropyl alcohol (C) was initiated. Between 6.5 min and 7 
min solvent B (95%) was gradually replaced with solvent C (95%). The mobile phase was then 
held at 5% A 95% C until 7.5 min before gradually returning to initial conditions (87% A, 13% 
B, 0% C) after 8.5 min, which were maintained for 1.5 min prior to the next injection. The flow 
rate was 300 µl/min and the injection volume was 5 µl. The column oven temperature was set to 
40°C. C2E5 was detected on a triplequadrupole mass spectrometer (Thermo TSQ Quantum 
Access) using electrospray ionization (ESI) in the positive-ion mode. The ionization source and 
collision parameters were optimized to give maximum analyte signal intensity (Spray Voltage 
3500V; Sheath and Auxiliary gas nitrogen, 10 and 25 psi, respectively; Collision gas Argon @ 
1.5 mTorr; Collision energy 35 eV). The mass spectrometer was set to carry out single reaction 
monitoring (SRM) for the precursor → product ion transitions m/z 534 → 216 (C2E5) and m/z 
506 → 188 (C2E4) at a retention times of 3.6 and 2.8 min, respectively.  For C2E5 
quantification, a calibration plot of analyte peak area against nominal C2E5 concentration (20 – 
1000 ng/ml) was constructed from a quadratic equation with a 1/concentration2 weighting. 	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Data analysis. The data were processed by Graph Pad Prism 5.0, and are presented as 
mean ± SEM.  
4.3 Results  
To compare the inhibitory effects of the excipients on human skin S9 fraction-mediated 
hydrolysis of C2E5, the loss of parent drug C2E5 was assessed by LC/MS/MS analysis (Fig. 4.1-
4.7). The evaluated concentrations of the test excipients were 0.1, 1, 10, and 100 µg/ml. The data 
produced from human skin S9 fraction-mediated C2E5 hydrolysis without the presence of any 
excipients were used as negative controls and they were set as 100%. Therefore, any samples 
generated with the pre-incubation of the excipients were measured and compared with this 
control.  
SLS and Tween 20 were reported to have inhibitory effect on CESs by PNPA assays 21, 
therefore, we used 100 µg/ml of SLS and Tween 20 as positive control for this study. This means 
that it is expected to see reduction in percent of loss of C2E5 (hydrolysis) from the samples that 
were pre-incubated with SLS and Tween 20. Preferably, those inhibition patterns from SLS and 
Tween 20 should exhibit in a concentration-dependent manner.  
Inhibition of C2E5 metabolisms were measured and quantified. The data displayed (Fig 
4.1-4.7) were produced by normalization of the relative reduction of the hydrolyzed C2E5 to 
negative controls that were defined in the first paragraph. The samples with pre-incubation of 
Miglyol 840 (100 µg/ml), Eudragit RLPO (100 µg/ml), Crodamol EO-LQ-(MH) (100 µg/ml) 
and Brij 72 (100 µg/ml) as well as SLS (100 µg/ml) and Tween (100 µg/ml) indicated 
remarkable inhibitions of C2E5 hydrolysis. For example, only 49.12% of the loss of C2E5 
occurred in sample that was pre-incubated with Miglyol 840 (100 µg/ml) in contrast to 100% of 
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the loss of C2E5 occurred in samples without pre-incubation of Miglyol 840. However, Miglyol 
840 (0.1-10 µg/ml) did not exhibit significant inhibitory effect. Miglyol 812 (100 µg/ml) 
inhibited the enzyme-mediated hydrolysis moderately (Fig 4.2). Among all the excipients, SLS 
and Tween 20 inhibited the C2E5 hydrolysis the most (Fig 4.7). Eudragit RLPO (0.1-100 µg/ml) 
showed slightly inhibitory effects on C2E5 hydrolysis. On the contrary, Eudragit RSPO (0.1-100 
µg/ml) stimulated C2E5 hydrolysis by 2.5-fold to controls (without excipients). The remaining 
excipients had a negligible effect.   
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4.4 Discussion  
  This study focused on the effects of individual excipients on human skin S9 fraction- 
mediated C2E5 hydrolysis.  An LC/MS/MS method was developed and validated to measure 
human skin S9 fraction-mediated prodrug C2E5 hydrolysis in the absence and presence of 
excipients.  This approach allowed for rapid and sensitive assessment to both controls and test 
samples. The effects of all excipients were measured in vitro using human skin S9 fractions.  
  The findings provide initial safety information of excipients used in the transdermal 
delivery formulations, particularly for multiester-based prodrugs. Miglyol 840 and 812 are used 
not only in transdermal delivery, but also in topical and intramuscular formulations 10. The fact 
that they exert inhibitory effects on ester hydrolysis at concentrations of 100 µg/ml might help to 
explain the compromised drug actions of ester-based prodrugs. From this study, it is suggested 
that, among the excipients analyzed, Capmul MCM, Capmul MCM EP, Captex 335 and 
polyoxyethylene tridecyl ether are appropriate excipients for transdermal formulations of 
multiester-based prodrug. The others can be used for transdermal formulation at concentration 
less than 100 µg/ml.  
The inhibitions of skin metabolic enzymes caused by these excipients are not necessarily 
concentration-dependent inhibitions. This might be attributed to the denaturation and 
precipitation of the proteins or enzymes in human skin S9 fractions. This caused them to lose 
their 3-dimensional structures and become incapable of metabolizing C2E5.    
In contrast to all the other test excipients, Eudragit RSPO increased the hydrolysis of 
C2E5. Usually multiple excipients are employed in transdermal formulations. However, this 
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study did not investigate the synergistic effects of combinations of excipients, therefore, the 
studies on these effects could become the future directions.  
Currently, studies on cutaneous metabolism are limited to the knowledge on using the 
appropriate model for evaluating biotransformation in transdermal delivery. Usually, pig skin or 
rat skin is used to evaluate the permeability, metabolism and absorption of drugs 22, 23. However, 
it is also known that species-differences do exist among those models 24. The data generated from 
those animal models should be extrapolated carefully to human. Therefore, the use of human 
skin S9 fractions is a rational approach to assess drug metabolism in human skin. Previous 
chapters of this dissertation describe the characterization of CES-mediated hydrolysis of C2E5 in 
human skin S9 fractions. However, certain limitations of using human skin S9 fractions still need 
to be addressed, such as batch-to-batch differences in human S9 fractions, collected from 
different patients and genetic polymorphisms that could alter the activity of CESs in the skin, 
which could lead to differences in the skin S9 fraction-mediated hydrolysis.  
   Broadly speaking, these findings also have important clinical implications. Individuals 
with CESs polymorphisms that produce a poor CESs phenotype may be at increased risk of 
experiencing drug interactions that involve with CESs substrates and inhibitors. However, when 
this is applied to C2E5 transdermal delivery, it is unlikely to cause drug-drug interactions as long 
as the co-administered drugs do not pass through skin. Miglyol 840, Miglyol 812, Eudragit 
RLPO, and Crodamol EO-LQ- (MH) affect ester-based prodrug hydrolysis in the skin because of 
their delivery sites, suggesting that they do not affect the ADME properties of co-administered 
drugs from other routes.  
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  In summary, the effect of twelve excipients used in transdermal formulations on the 
hydrolysis of C2E5 was investigated. Human skin S9 fractions were used to study cutaneous 
metabolism. Within the tested concentration range, Miglyol 840, Eudragit RLPO, Cromdamol 
EO-LQ- (MH), Brij 72 showed inhibitory effect at 100 µg/ml. Zhang’s reported that SLS and 
Tween 20 can inhibit CESs activity, evaluated by PNPA assay 21. In our study, SLS and Tween 
20 also inhibit CES-mediated prodrug C2E5 hydrolysis at a concentration of 100 µg/ml. In 
contrast, Eudragit RSPO (0.1-100 µg/ml) increased the C2E5 hydrolysis. The remaining 
excipients had smallest effect. This study initiates the safety concerns for excipients used in 
transdermal delivery and emphasizes the importance of selecting appropriate surfactants for 
multiester-based prodrugs. 
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Figure 4.1. The effects of Miglyol 840 at various concentrations (0, 0.1, 1, 10 and 100 µg/ml) on 
the hydrolysis of C2E5 in human skin S9 fractions. Miglyol 840 were incubated with human skin 
S9 fractions for 30 min at 37°C before the reaction was initiated. Loss of parent drug was 
measured by detecting changes in spectromatogram at the LC/MS/MS analyte peak (3.6 min) 
after 120 mins incubation of 0.5 µM C2E5 with human skin S9 fractions with and without 
Miglyol 840. Values represent mean ± SEM (n=3). 
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Figure 4.2. The effects of Miglyol 812 at various concentrations (0, 0.1, 1, 10 and 100 µg/ml) on 
the hydrolysis of C2E5 in human skin S9 fractions. Miglyol 812 were incubated with human skin 
S9 fractions for 30 min at 37°C before the reaction was initiated. Loss of parent drug was 
measured by detecting changes in spectromatogram at the LC/MS/MS analyte peak (3.6 min) 
after 120 mins incubation of 0.5 µM C2E5 with human skin S9 fractions with and without 
Miglyol 812. Values represent mean ± SEM (n=3). 
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Figure 4.3. The effects of Eudragit RLPO at various concentrations (0, 0.1, 1, 10 and 100 µg/ml) 
on the hydrolysis of C2E5 in human skin S9 fractions. Endragit RLPO were incubated with 
human skin S9 fractions for 30 min at 37°C before the reaction was initiated. Loss of parent drug 
was measured by detecting changes in spectromatogram at the LC/MS/MS analyte peak (3.6 
min) after 120 mins incubation of 0.5 µM C2E5 with human skin S9 fractions with and without 
Eudragit RLPO. Values represent mean ± SEM (n=3). 
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Figure 4.4. The effects of Eudragit RSPO at various concentrations (0, 0.1, 1, 10 and 100 µg/ml) 
on the hydrolysis of C2E5 in human skin S9 fractions. Endragit RSPO were incubated with 
human skin S9 fractions for 30 min at 37°C before the reaction was initiated. Loss of parent drug 
was measured by detecting changes in spectromatogram at the LC/MS/MS analyte peak (3.6 
min) after 120 mins incubation of 0.5 µM C2E5 with human skin S9 fractions with and without 
Eudragit RSPO. Values represent mean ± SEM (n=3). 
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Figure 4.5. The effects of Crodamol EO-LQ-(MH) at various concentrations (0, 0.1, 1, 10 and 
100 µg/ml) on the hydrolysis of C2E5 in human skin S9 fractions. Crodamol EO-LQ-(MH) were 
incubated with human skin S9 fractions for 30 min at 37°C before the reaction was initiated. 
Loss of parent drug was measured by detecting changes in spectromatogram at the LC/MS/MS 
analyte peak (3.6 min) after 120 mins incubation of 0.5 µM C2E5 with human skin S9 fractions 
with and without Crodamol EO-LQ-(MH). Values represent mean ± SEM (n=3). 
 
 
 
	   88	  
 
 
Figure 4.6. The effects of Brij 72 at various concentrations (0, 0.1, 1, 10 and 100 µg/ml) on the 
hydrolysis of C2E5 in human skin S9 fractions. Brij 72 were incubated with human skin S9 
fractions for 30 min at 37°C before the reaction was initiated. Loss of parent drug was measured 
by detecting changes in spectromatogram at the LC/MS/MS analyte peak (3.6 min) after 120 
mins incubation of 0.5 µM C2E5 with human skin S9 fractions with and without Brij 72. Values 
represent mean ± SEM (n=3). 
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Figure 4.7. The effects of SLS and Tween 20 at various concentrations (100 µg/ml) on the 
hydrolysis of C2E5 in human skin S9 fractions. SLS and Tween 20 were incubated with human 
skin S9 fractions for 30 min at 37°C before the reaction was initiated, respectively. Loss of 
parent drug was measured by detecting changes in spectromatogram at the LC/MS/MS analyte 
peak (3.6 min) after 120 mins incubation of 0.5 µM C2E5 with human skin S9 fractions with and 
without SLS or Tween 20. Values represent mean ± SEM (n=3). 
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CHAPTER 5 
GENERAL DISCUSSIONS AND CONCLUSIONS	  
	  
 The studies undertaken in this dissertation project have focused on deciphering the role of 
CESs in the metabolism of C2E5, a penta-ethyl ester prodrug for DTPA, to provide information 
for the development of C2E5 as a formulation for oral and transdermal deliveries. The findings 
on the metabolic mechanism of C2E5 provide important insights into prodrug formulation 
strategies, and establish a model for future possible multi-ester or amide-based prodrug 
development.  
Studies reported in chapter 2 demonstrated that C2E5 is hydrolyzed in the liver, intestine, 
and plasma of humans, dog and rat, and that the metabolic profiles of C2E5 are different among 
humans, dog and rat. The major metabolites of prodrug C2E5 in humans and dog are C2E4 as 
opposed to C2E2 in rat. Differences in the expression of CESs isoforms among the three species 
contribute to differences in C2E5 metabolism. Dog is a better predictive model for C2E5 
metabolism in humans, whereas the rat is important for understanding the potential toxicity of 
C2E5 metabolites. These findings clearly suggest that laboratory animal models (e.g., rodents, 
dogs) may not always be suitable for prediction of ADME profiles of prodrugs in humans. This 
information led us to confine further analysis of C2E5 metabolism to only human tissues.   
In humans, C2E5 was metabolized to the greatest extent in the liver, with a greater 
contribution by CES1 to C2E5 metabolism, compared to CES2. Therefore, it is
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likely that the rapid conversion of C2E5 to its metabolites in the liver is due to higher hepatic 
CES1 expression. Based on the chemical structure of C2E5 and the high expression of hepatic 
CESs, it was expected that C2E5 would be extensively metabolized to DTPA in the liver, 
indicating that oral delivery would be advantageous to C2E5 prodrug formulation strategy. 
Moreover, the fact that C2E5 was converted to C2E2, an active chelator, provides evidence of an 
effective prodrug design. 
CESs play an important role in metabolizing endogenous and xenobiotic compounds for 
detoxification. CES isoforms 1b, 1c and 2, expressed in the liver and intestine, are responsible 
for C2E5 hydrolysis. Both CES1 and CES 2 are important for metabolism of the prodrug C2E5, 
and CES1 metabolizes C2E5 slightly more readily than CES2. This is likely due to the fact that 
the smaller and shorter chain of ethyl-esters in C2E5 cause it to preferably fit the cavity of the 
CES1 enzyme.  
The data from chapter 3 reports the characterization of gene and protein expression of 
CES isoforms in multiple human skin cell lines and human skin tissue.  This study confirmed 
that CESs are present as metabolic enzymes in the keratinocytes. Although these enzymes are 
expressed at lower levels in the skin than in the liver, specifically CES2 compared to CES1, the 
capacities of CESs for xenobiotic metabolism in the keratinocyte cell lines analyzed in this study 
are substantial. Because these keratinocyte cell lines are comparable to that of human skin, they 
can be used as alternative models for cutaneous metabolism studies in transdermal drug delivery. 
Overall, the data presented in chapter 3 provide evidence that metabolic enzymes in the skin 
enhanced transdermal delivery of C2E5 in vitro.  
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 Studies reported in chapter 3 demonstrated that CES1 in human skin S9 fractions readily 
metabolizes C2E5, and corroborate data in chapter 2 that demonstrated that C2E5 is a preferable 
substrate for the human recombinant CES1.  
Since biotransformation of C2E5 in transdermal delivery would commence as soon as it 
enters skin cells, patients affected by idiosyncratic alterations in CES1 cutaneous expression may 
demonstrate variability in the absorption of C2E5. The higher expression of CES1 in human skin 
would result in a faster conversion of C2E5 into C2E4, a charged molecule, which potentially 
diffuses into the systemic circulation more readily than C2E5 due to its physiochemical 
properties. Once C2E4 and unchanged C2E5 reach the system circulation, a majority of the 
C2E5 would be metabolized in the liver, and to some extent in the intestine; this pathway is 
supported by results reported in Chapter 2. Studies described in chapters 2 and 3 collectively 
demonstrated this C2E5 transdermal delivery metabolic pathway (Fig 5.1).  Compared to the 
hepatic and intestinal metabolism of C2E5, human skin metabolism of this prodrug is less 
efficient. However, since the transdermal delivery route would bypass first-pass metabolism, it 
suggests that the skin would be the first metabolic organ, as well as a reservoir that controls drug 
release, and therefore, would affect the absorption and subsequent fate of the drug.  
    Although this is not the first study to characterize CESs in human skin, it is the first study 
to relate gene expression, protein expression and enzyme activities in each of the four human 
keratinocyte cell lines and skin tissue. The relatively higher gene expression of CES2 compared 
to CES1 in the different cell lines is consistent with protein expression. Nevertheless, certain 
factors such as cell passage number; cell culture conditions and the origin of the donor cells 
could influence the expression and activities of CESs.    
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Chapter 3 provides evidence that CESs in human skin are advantageous to C2E5 
transdermal delivery; therefore, it is important to study the effect of excipients commonly used in 
transdermal formulations on C2E5 hydrolysis (reported in chapter 4). Since different CESs 
isoforms show differences in substrate recognition that can lead to dramatic interspecies 
differences in enzyme activity in the skin, the effect of the transdermal excipients evaluated in 
human skin S9 fractions would more accurately relate to their in vivo behavior in humans. 
Results from this experiment clearly show that some of the transdermal excipients act as 
modulators of enzyme-excipient interactions, which is likely due to excipient-induced 
conformational change in the metabolic enzymes in human skin S9 fractions.   
 CESs, the most important members of the esterase family, work to catalyze reactions 
with their Ser-His-Glu triads (catalytic domain) 1. The hydrophobic chains form non-ionic 
excipients that could interfere with the catalytic domains of the CESs, thus impeding CES-
mediated hydrolysis of C2E5.   
The effect of excipients on CES-mediated hydrolysis of C2E5 in human skin S9 fractions 
(reported in chapter 4) could also be determined using an alternative approach that evaluates 
excipient-drug interactions in silico. Evidence from protein formulation research showed that 
protein-excipient interactions affect the stability of protein medicine or other macromolecule 
drug 2. It proposed that key mechanisms of protein-excipient interactions are related to 
electrostatic interactions, preferential hydration, dispersive forces, and hydrogen bonding in the 
context of different physical states of the formulation. 
On the other hand, current research by other investigators also employs in silico 
molecular simulation of excipients, in combination with drugs, to predict the selection of the 
most suitable excipients for transdermal drug delivery 3.For example, human skin in Franz 
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Diffusion cell system 4 was used to predict the effect of impurities in topical formulations. The 
study results have ranked the impurity risk priority of 20 excipients. The mathematical 
quantifications are a rapid tool to provide a general concept of excipient safety, which is 
mandated by Good Manufacturing Practice (GMP) guidelines for dermal excipients. However, 
those types of approaches have their own advantages and limitations compared to our in vitro 
methods. Although computational studies quantitatively estimate the mechanism of excipient-
protein interactions, those theoretical data cannot fully describe the biological environment at the 
cellular level. On the contrary, human keratinocyte cell lines are derived from human skin and 
are representative of human skin tissue; therefore, data obtained from using human skin cell lines 
provide valuable insights into CES-mediated metabolism of drugs delivered transdermally in 
humans. A combination of our experimental results with computational modeling to elucidate 
excipient and enzyme interactions would be a good strategy.  
 Most transdermal delivery excipients are surfactants that are generally used in protein 
formulations to inhibit protein aggregation caused by agitation or shaking. However, studies 
have shown that non-ion surfactants could directly interact with hydrophobic regions in protein-
based drugs, which raises the concern that the excipients could act as competitive inhibitors of 
protein adsorption or protein surface denaturation which could occur in a concentration-
dependent manner 5, 6. Some excipients could contain peroxides, which can oxidize proteins, 
while others could be degraded by either oxidation or hydrolysis, which affects protein or 
enzyme stability.  
In summary, this dissertation highlights the interspecies differences in CES isoforms that 
catalyze penta-ethyl ester prodrug, resulting in differences in the pharmacokinetics of C2E5. It 
also provides an explanation for how differences in the structure and activities of CES1 and 
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CES2 contribute to dissimilarities in their metabolism of DTPA prodrugs. This information is 
useful for future DTPA prochelator drug design. This work also describes the metabolic path 
involved in the sustained release of C2E5 by non-aqueous gel transdermal delivery. As the first 
investigation of CES expression in human keratinocyte cell lines and skin tissue, it also clearly 
demonstrates that CES1 in the skin metabolizes transdermally delivered C2E5. Lastly, the 
common excipients used in transdermal delivery had varying effects on CES-mediated C2E5 
hydrolysis, underscoring the importance of selecting appropriate excipients in future 
formulations.  
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Figure 5.1. Proposed biotransformation pathway for C2E5 during transdermal delivery. C2E5 
crosses the stratum corneum, and can passively diffuse into keratinocytes. Metabolism of C2E5 
by CESs in keratinocytes results in the formation of metabolite C2E4 that are more hydrophilic 
than C2E5.  Meanwhile, it is unlikely that C2E5 will go through the paracellular route because it 
is large in size to pass through the intercellular space. Metabolites and unchanged C2E5 
eventually reach the systemic circulation and are totally converted to C2E4 in the liver and other 
metabolizing tissues.  
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CHAPTER 6 
FUTURE DIRECTIONS 
	  
	  
In this study, we found that the interspecies differences in prodrug C2E5 metabolism are 
likely due to differences in CES isoform expression profiles among different species. However, 
currently, knowledge on CES characterization in different species is limited. Although studies 
have suggested similarities in rat and pig CES to that of humans, some of the protein crystal 
structures of CES isoforms in the different species have not been crystalized. Protein crystal 
structures provide important information that is useful for simulations and docking experiments. 
In studies reported in the following appendices, we attempted to dock human CES1 with C2E5 
metabolites by selecting human CES crystal structure published in the National Center for 
Biotechnology Institute database. However, these studies (in the appendices) only generated 
results that describe how human CES interacts with C2E5. Therefore, a future direction would be 
to explore interspecies differences at the molecular level by docking human, rat and dog CESs 
with C2E5 to examine enzyme-drug interactions and elucidate mechanisms of interspecies 
differences.   
In addition, we also have found that human skin cell lines could be used as alternative 
models for elucidating cutaneous metabolism of drugs that are transdermally delivered in 
humans. Although we utilized keratinocytes isolated from the complex anatomy of the skin to 
characterize its cellular metabolic function, other epidermal cell types, such as fibroblasts, were 
not included in these studies, as this was beyond the scope of this dissertation project.  
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Although cell lines are simple tools for assessing cutaneous metabolism, they cannot 
demonstrate the effect of physiological features of skin tissue on drug metabolism and 
absorption. For example, the abundance of blood vessels, types of appendages such as hair 
follicles and sebaceous glands, and Langerhans cells could alter the absorption pathway of drugs 
by transdermal delivery. Therefore, a 3-dimensional cell model could be utilized to assess the 
impact of physiological factors on C2E5 hydrolysis.  
 The effect of excipients on prodrug C2E5 hydrolysis, determined in this study using an in 
vitro model, emphasizes safety issues associated with excipients used in transdermal delivery. 
The in vitro study serves as a rapid tool to assess excipient-enzyme interactions; however, data 
obtained from these in vitro experiments cannot be easily extrapolated to the whole body. 
Therefore, a possible study in the future would be to conduct clinical studies to investigate the 
combined effect of multiple excipients used in transdermal formulations.   
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APPENDIX A: HUMAN CARBOXYLESTERASES TRANSFECTION 
	  
Introduction 
	  
Bacterial transformation is the process of introducing foreign DNA into the competent 
bacteria. Foreign DNA usually is incorporated by a plasmid vector, which can introduce a gene 
fragment to the host bacteria easily. Plasmid DNA is usually short, easily replicated, and have an 
independent circular chromosome with an origin of replications. Replication origin is a particular 
sequence in a genome at which replication is initiated. As a result, they are used widely as gene 
vectors.  Plasmid chromosome replicates independently from the bacteria chromosome, and can 
be easily separated from the bacteria chromosome. Plasmid vector carriers a negative charge and 
the surfaces of the bacteria membrane also are negatively charged, therefore, plasmid vector and 
bacteria cells repulse each other under natural conditions. In order to insert the plasmid vector to 
the bacterial cells, calcium phosphate methods, electroporation, and heat shock methods could be 
applied.  
In order to test the transfection efficiency, certain reporter protein can be co-transfected 
as an indicator.  It is also well known that green fluorescent protein (GFP) can be used for co-
transfection. Therefore, it is necessary to know the properties of GFP. GFP is found in jellyfish, 
which consists of 238 amino acids with a size of 27 KDa 1 . The green fluorescent protein (GFP) 
has a chromophore creating the fluorescent; its autocatalytic activity is generated by protein 
conformation, yielding an interaction between arginine and tyrosine residues. This chromophore 
absorbs UV light and fluoresces green signals. GFP has a structure of “11 Betastrands forming a 
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hollow cylinder through which is treaded a helix bearing the chromophore” 2 . Because GFP is a 
vital tool in several subfields of biology and biochemistry, it is widely used in protein 
localization studies, regulation and expression studies, cell sorting and other analytical 
techniques. 
   Currently, the penta-ethyl ester prodrug of the chelating agent diethylene triamine 
pentaacetic acid (DTPA), referred to as C2E5, is being developed for radionuclide decorporation. 
Carboxylesterases (CESs) are important contributors to the metabolic pathways of xenobiotics, 
including prodrugs. It is necessary to use genetic engineering methods to produce purified human 
recombinant protein to examine which isoform of carboxylesterases, if any, is most vital for 
C2E5 hydrolysis. Therefore, The objective of this study was to utilize competent E. coli 
(DH5alpha) bacteria to replicate a specific human CES plasmid DNA. The second objective was 
to apply genetic engineering technology to incorporate the GFP gene as a reporter to exam the 
hCES1 and hCES2 transfection efficiency in HEK293 cells for scaling up the quantity of the 
hCES1 and hCES2. Those transfected cells can be easily visualized under fluorescent 
microscopy as so the percent of the transfected cells can be estimated. The third objective was to 
measure the activities of the produced human recombinant CESs.
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Materials and Methods 
	  
Chemicals.  
Competent Cells (DH5-ALPHA) and S.O.C media were purchased from Invitrogen. 
Plasmid DNA, pEGFP-N1 was obtained from Dr. Ming Xin at UNC-CH and positive control 
plasmid DNA pUC19, were purchased from OriGene.  Petri dish 60mm (+LB, +50µg/µl 
kanamycin) and petri dish, 60mm (+LB, +100µg/µl Ampicillin) were purchased from tissue 
culture facility of UNC and were manufactured by CellTreatTM (Shirley, MA). The complete 
DMEM (10% FBS, 1% Pen/Strep) growth medium was obtained from TCF as well. TurboFect 
TM transfection reagent was purchased from thermo fisher scientific. RT-qPCR materials with 
cyber green (SYBR) were purchased form Bio-Rad.  
Transfection of human carboxylesterases to HEK293 cells.  
HEK293 cells were transfected with plasmid DNA which carries hCES1, hCES2. 
Meanwhile, empty vector was transfected as negative control, and pEGFP plasmid was 
transfected as a positive control. Plasmid DNA samples were produced from E. coli bacterial 
transformation. The growth of the transformed bacteria colony took place in LB culture media. 
The transformant was produced in a large quantity and plasmid DNA was isolate by mini prep 
(Qiagen).  
Transfection efficiency measured by GFP reporter.  
In a six-well cell culture plate, HEK293 cells were seeded 24 h prior to transfection. 
(Confluency for adherent cells on the day of transfection is 60-80%.) Then hCES1 (2 µg) 
plasmid DNA and GFP plasmid DNA (2 µg) were added to pre-warmed DMEM medium (400 
µl). TurboFectTM   reagent (6 µl) was subsequently added to this mixture. The same procedure 
applied to hCES2 plasmid DNA. TurboFectTM (6 µl) reagent was added to the previous made 
	   105	  
mixture as the mock vector. DNA and transfection reagent mixture was incubated for 15-20 
minutes at room temperature. Then the TurboFectTM/DNA mixture was added to cells and 
incubated for 48 h. Transfection efficiency was observed by fluorescent microscopy. 
S9 fractions prepared from transfected cells.  
Supernatant (S9) fractions were prepared from HEK293 cells expressing human CES 1 
(NM_001266.4) or CES 2 (NM_00369.4). The method was described in chapter 2 and chapter 3.  
For all cell lines, cytosolic S9 fractions were prepared as described as follows. Briefly, cells were 
washed with ice-cold PBS and then removed from the culture dish with a cell scraper, suspended 
in PBS and homogenized in a Potter-Elvehjem glass homogenizer with a Teflon pestle under ice-
cold condition. After centrifugation of the cell homogenate at 9000g for 15 min at 4°C, then the 
S9 fractions were obtained. Protein concentrations were determined by the Bradford method with 
bovine serum albumin used as the standard.  
CESs expression confirmed by RT-PCR  
The relative RNA expression levels were determined by the delta Ct method. The amount 
of target gene expression was calculated using the expression of the GAPDH gene as an internal 
control. The CESs mRNA levels were given as ratios to the GAPDH mRNA levels. Triplicate 
real-time RT-PCR assays were carried out for each sample. Regarding sample analysis, it was 
normalized to the GAPDH comparative CT (ΔΔCT) [ΔCt = Ct[Target]-Ct[Gapdh]], and samples were 
analyzed in triplicate [Standard Deviation Error Bar = -FOLD + FOLD x (2Ct Dev.)].  
Functional studies by PNPA and 4-NPV  
The enzyme activity of esterase and CESs were measured using established substrates 
para-nitrophenyl acetate (PNPA) and 4-nitrophenyl valerate (4-NPV), respectively. The 
hydrolysis of the freshly prepared substrates was carried out in 96 well plates with a total volume 
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of 100 µl/well. Bis(p-nitrophenyl) phosphate (BNPP), a CESs inhibitor was used to confirm the 
presence of carboxylesterase. Loperamide, a CES2 specific inhibitor, further was used to confirm 
the presence of CES2. Inhibitors were added to the human recombinant protein S9 fractions for 
30 minutes, following, the reactions were initiated by mixing 1 µl of substrate (PNPA or 4-
NPV). The hydrolysis of PNPA and 4-NPV were determined spectrophotometrically by 
measuring reaction products at 402 nm after 1 min incubation at 37°C. The data generated from 
the plates were read by a UV spectrophotometer (BioTek, VT). All the data was measured in 
triplicate. 
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Results 
Transfection of human carboxylesterases.  
Newly generated hCES1 plasmid DNA sample is 0.8708 μg/μl, hCES2 plasmid DNA 
sample is 0.4734 μg/μl, GFP plasmid DNA sample is 1.591 μg/μl, and renilla plasmid DNA 
sample is 0.8231 μg/μl. Those entire prepared plasmid DNA sample has an A260/A280 ratio 
greater than 1.8, which indicates that the prepared DNA samples has a decent quality.  Among 
them, hCES1, hCES2 and GFP plasmid DNA will be used for transfection steps in the following 
studies.  The data of plasmid concentrations were summarized in Table A.1.  
Transfection efficiency measured by GFP reporter.  
GFP reporter gene was transformed in competent E. coli bacterial cells, and was isolated 
and purified from the bacteria genome, then was transfected with hCES1 and hCES2 plasmid 
DNA to HEK293 cells through cationic polymer transfection agent, TurboFectTM (Fig A.2). The 
results from transfection study were monitored by fluorescence microscopy. Gross observations 
of the green fluorescence can be used to estimate the amount of transfected cells. After 24 h of 
transfection, only 10% of cells were transfected, however, after 48h of transfection, about 50% 
of the cells were transfected, on the other hand, certain cytotoxicity was observed after 48 h of 
transfection.  
 
CES expression confirmed by RT-qPCR.  
Genetic expression of CES1 and CES2 were both detected in cells that were transfected 
with CES1. Genetic expression of CES2 was both detected in cells that were transfected with 
CES2.  
 
 
	   108	  
Functional studies by PNPA and 4-NPV.  
Functional studies using the esterase specific substrate p-nitrophenylacetate (PNPA) and 
carboxylesterase-specific substrate 4-nitrophenyl valerate (NPV) confirmed the esterase activity 
of these S9 fractions. On the other hand, bis(p-nitrophenyl) phosphate (BNPP), significantly 
inhibited CESs-mediated PNPA and 4-NPV hydrolysis. On the other hand, loperamide, a CES2 
specific inhibitor, significantly inhibited the activities of CES2 in S9 fractions generated from 
transfected HEK293 cells, confirming the presence of CES2.  
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Discussions 
CESs are important contributors to the metabolic pathways of xenobiotic. Many prodrugs 
are designed to be converted into active drugs by CESs. Genetic engineering and recombinant 
protein technology have been established for decades. With those techniques, pharmaceutical 
scientists can isolate a single protein or enzyme from the complex biological systems and then 
use purified protein or enzyme for drug development, for example, protein formulations. In this 
study, competent E. coli (DH5alpha) bacteria were used to replicate a specific human CES gene 
what was inserted to pCMV6-XL4 mammalian expression vectors (Origene). The data from 
table1 showed that the production of plasmid DNAs from bacteria were successful. These 
plasmid DNAs can be used for transfection in mammalian cell lines.  
The gene from GFP protein was used as a reporter to examine the hCES1 and hCES2 
transfection efficiency in HEK293cells for scaling up the quantity of the hCES1 and hCES2. The 
percent of the transfected cells was estimated. While optimizing the condition for transfection, 
several factors could affect the transfection of mammalian gene, for example, transfection time, 
serum or serum free media, and pDNA/transfect agent ratio. This study showed that the 
transfection time played as an important role in determining transfection efficiency. According to 
the observation, the number of cells that express transfected GFP protein increased from 40% in 
24h to 70% in 48h. At the same condition, cells that were treated with serum-rich media or 
serum-free media were compared and the result showed that cells expressed more GFP protein in 
serum-free media. Following, the samples transfected with 4 µg of pDNA and 6 µg of pDNA 
were compared, and the results showed that the one transfected with 6µg of pDNA produced 
better GFP protein expression.  
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PCR result (Fig A.3) did show that CES were expressed in human HEK293 cells. 
However, there is slightly higher CES2 that are also expressed in the cells transfected with 
CES1. This could be a noise from the assay. Other common methods used to examine if the 
correct pDNA is transfected are DNA gel electrophoresis or DNA sequencing. Gel 
electrophoresis can be used to identify qualitatively if the gene of interest is present. In contrast, 
DNA sequencings are used for checking the entire sequences of the nucleic acids.  
BNPP is an inhibitor for both esterase and cholinesterase. Loperamide is commonly used 
as CES2 specific inhibitor. This study has shown that they can inhibit the esterases and CES2 
activities in human recombinant protein S9 fractions (Fig A.4 and A.5). However, this inhibition 
was short-term.  
In conclusion, a human recombinant CESs expression system was established. The 
recombinant CESs S9 fractions were isolated and the activities of CESs were characterized.  
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Figure A.1. GFP protein three-dimensional structure  
 
 
 
 
 
 
 
 
 
Figure A.1 
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Table A.1. Plasmid DNA (hCES1, hCES2, GFP, and Renilla plasmid DNA) concentrations were 
measured prior to the transfection in HEK293 cell lines.  
Plasmid DNA Concentration Determination 
Plasmid  Trial 1 Trial 2 Trial 3 Average 
(ng/µl) 
STDEV 
(ng/µl) 
 Percent of 
variation (%) 
hCES1  870.63 869.06 872.59 870.76 1.768587 0.20 
hCES2 472.78 472.98 474.41 473.39 0.888988 0.19 
GFP 1600.95 1593.83 1578.87 1591.217 11.26959 0.70 
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Figure A.2. HEK 293 cells were transfected with pEGFP to establish the optimal transfection 
condition for human CESs plasmid DNA. Group A shows transfection at 24 h, and group B 
shows transfection at 48hr. “+”=serum media, “-”=serum free media  
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Figure A.3. The evaluation of human CES1 and CES2 genetic expression in transfected HEK293 
cells by RT-qPCR.  
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Figure A.4. Recombinant protein S9 fraction-mediated hydrolysis was measured by PNPA 
assays. Esterases inhibitors (BNPP) and carboxylesterase inhibitor (loperamide) were used to 
inhibit CESs activities to demonstrate that esterase and CES2 are present in human recombined 
protein. Inhibitors were added to the human recombinant protein S9 fractions for 30 minutes, 
following, the reactions were initiated by mixing 1µl of substrate (PNPA). The hydrolysis of 
PNPA and 4-NPV were determined spectrophotometrically by measuring reaction products at 
402 nm after 1 minute incubation at 37°C. 
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Figure A.5. Recombinant protein S9 fraction-mediated hydrolysis was measured by 4-NPV 
assays. Esterases inhibitors (BNPP) and carboxyl esterase inhibitor (loperamide) were used to 
inhibit CESs activities to demonstrate that esterase and CES2 are present in human recombinant 
protein. Inhibitors were added to the human recombinant protein S9 fractions for 30 minutes, 
following, the reactions were initiated by mixing 1µl of substrate (4-NPV). The hydrolysis of 
PNPA and 4-NPV were determined spectrophotometrically by measuring reaction products at 
402 nm after 1 min incubation at 37°C. 
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APPENDIX B: A COMPARISON OF  SKIN METABOLISM IN ADULT AND JUVENILE 
RATS	  
Introduction  
	  
Previously, we have determined that CESs play an important role in C2E5 hydrolysis. 
The penta-ethyl ester prodrug of the chelating agent DTPA, referred to as C2E5, effectively 
decorporates transuranic radionuclides after transdermal delivery, an attractive route of 
administration for treating contaminated pediatric populations. Previous study showed that C2E5 
can be hydrolyzed by adult rat skin S9 fractions. However, whether the skin S9 fractions of 
juvenile rats have the same metabolic capacity to biotransform prodrug C2E5 remains unknown. 
Therefore, the objectives of the current work is to compare the esterases activity in the skin of 
adults rat with that of juvenile rats and assess the C2E5 hydrolysis in juvenile rats skin S9 
fractions.  
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Methods 
	  
CESs activities in rats skin measured by ρNPA  
The enzyme activity of esterase was measured using established substrates para-
nitrophenyl acetate (ρNPA). The hydrolysis of the freshly prepared substrates was carried out in 
96 well plates with a total volume of 100 µl/well. Following, the reactions were initiated by 
mixing 1 µl of substrate (ρNPA) to the adult and juvenile rat skin S9 fractions. The hydrolysis of 
ρNPA were determined spectrophotometrically by measuring the formation of products at 402 
nm at 1-10 mins at 37°C. The results generated from the plates were read by a UV 
spectrophotometer (BioTek, VT). All the data were measured in triplicate. 
Juvenile rat skin S9 fraction-mediated C2E5 hydrolysis measured by HPLC 
 [14C]-C2E5 (50 μM) was incubated in juvenile rat (postnatal 30-60 days) skin S9 
fractions for 0, 5, 15, 30, 60, 120, 360, and 1440 minutes at 37ºC. Following, the reactions were 
terminated at the indicated time points by the addition of an equal volume of cold ACN followed 
by centrifugation at 14,000g for 10 min at 4ºC. The disappearance of C2E5 was determined by 
radio-HPLC. 
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Results 
Comparison of CESs activities by juvenile and adult rat skin S9 fractions  
ρNPA assay was used to measure and compare the esterase activities from the juvenile 
(P30-60 days) and adult rat (> P60) skin S9 fractions. It showed that there are differences in rat 
skin S9 fractions-mediated ρNPA hydrolysis at the first minute. However, this difference starts to 
minimize as time of the reaction goes and eventually reached the same level at 10 minutes. 
Figure B.1 shows the esterase activities in adult rat skin and juvenile rat skin over the time 
course of 10 minutes.  Figure B.2 shows the comparison of the esterase activities in adult rat skin 
and juvenile rat skin at time of 10 minutes.  
C2E5 metabolism by juvenile rat skin S9 fraction    
Juvenile rat skin hydrolysis was quantified by HPLC-FSA. [14C]-C2E5 is hydrolyzed 
significantly over time course from 0-1440 minutes. It was seen that most of the C2E5 was 
converted into C2E4 at 30 mins. Then C2E4 reaches its maximum at 30 minutes, followed by 
slow conversion to C2E3 from 30 mins to 1440 mins.  
Discussion  
	  
The comparison of adult and juvenile animal studies may be useful to predict the 
potential differences in pediatric drug product development. Juvenile and adult rat skin S9 
fractions displayed similar esterase activities. The data also showed that the juvenile rat skin S9 
fractions metabolized C2E5. This implies the potential application of the non-aqueous gel 
formulation delivery of C2E5 to younger populations. In the future, human pediatric skin 
samples could be collected and used for human age-dependent metabolism investigations. Per 
the FDA pediatric product development guidance, juvenile animal studies may be extrapolated to 
human pediatric populations.  
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Figure B.1 
 
 
Figure B.1. The activities of esterases in adult and juvenile rat skin S9 fractions were measured 
by ρNPA assay at reaction time of 1, 4, 7, and 10 mins. The hydrolysis of ρNPA was determined 
spectrophotometrically by measuring reaction products at 402 nm at each time point at 37°C. 
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Figure B.2 
 
Figure B.2. A comparison of esterases activities in adult and juvenile rat skin S9 fractions were 
measured by ρNPA assay at reaction time of 10 mins. The hydrolysis of ρNPA was determined 
spectrophotometrically by measuring reaction products at 402 nm at each time point at 37°C. 
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Figure B.3 
 
Figure B.3. C2E5 hydrolysis by juvenile Spraguee Dawley rat skin S9 fractions. [14C]- 
C2E5 (50 µM) was added directly to rat skin S9 fractions (pre-warmed for 5 min at 37ºC). The 
reactions were terminated at the indicated time points (0, 5, 15, 30, 60, 120, 360, and 1440 mins) 
by addition of an equal volume of cold ACN followed by centrifugation at 14,000g for 10 min at 
4ºC. All the reactions were determined by radio-HPLC. All assays were performed in triplicate 
and were expressed as the mean ± SD. 
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APPENDIX C: MOLECULAR SIMULATIONS OF C2E5/C2EX BINDING TO 
HUMAN CARBOXYLESTERASE  
Introduction  
Maestro® is a powerful, all-purpose molecular modeling tool; it provides the 
unified interface for all Schrodinger software. It has powerful selection of analysis ability 
and has been well known for its user-friendly characters. The chemical simulation 
software of Maestro is mostly used in pharmaceutical, biotechnology, and materials 
science research. Maestro is written in Java language and it can be performed in many 
platforms, such as Microsoft, Windows, Macintosh, Solaris, Linux and Irix. The 
companion datasets can be obtained from Maestro headquarters. 
In molecular modeling, docking is a useful method to predict the best orientation 
of one ligand to another to form a stable complex. The calculation in the preferential 
orientation of the molecular complex can be used to predict the strength of the 
association. The relative orientation of the two interactive molecules also can tell the 
information about the type of signal produced.  It is a tool mostly used for predicting the 
binding orientation of small molecule drug candidates to their protein targets so as to 
predict the affinity and activity of the small molecule. Docking can be used to predict 
biological and pharmaceutical properties of small molecules.   
GlideScore is an empirical scoring function that approximates the ligand binding 
free energy. It has many terms, including force field (electrostatic, van der Waals) 
contributions and terms rewarding or penalizing interactions known to influence ligand 
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binding. It has been optimized for docking accuracy, database enrichment, and binding 
affinity prediction. GlideScore should be used to rank poses of different ligands, for 
example in virtual screening. While the XP GlideScore shares many terms with the SP 
and HTVS GlideScore, they do have significant differences and have been optimized 
separately; as a result, these two GlideScores cannot be compared directly. (Schrodinger, 
2011) 
Previously, the penta-ethyl ester of DTPA (C2E5) is expected to be metabolized 
in stepwise fashion to DTPA by the action of carboxylesterases, however, after both oral 
and transdermal administrations, the primary metabolites detected in plasma were the tri-
ethyl (C2E3) and di-ethyl (C2E2) esters of DTPA. In this study, the investigation is to 
determine why this is happening.  It is possible that this happens due to the increasing 
negative charge with each subsequent removal of an ethyl group.  In order to test this 
theory, DTPA prodrugs C2Ex and CxE2 can be docked with carboxylesterase crystal 
structures using the Maestro program. Molecular modelling is used to predict the position 
and orientation of the ligand when it is bound to a protein receptor or enzyme. The 
preferential bond energy, binding constant and affinity energy will be calculated based on 
the hydrodynamic of the molecule against with the enzyme. Considering the measureable 
enzymatic parameters, the interactions between ligands and protein, the information 
derived from docking would be able to explain metabolism obstacles of C2E5 to DTPA. 
Therefore, the objective is to develop docking system of human carboxylesterase 
complexed with C2E5 and its metabolites C2E4, C2E3, C2E2 and C2E1 to interpret the 
barrier in DTPA prodrug metabolism. 
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Methods 
Molecular Modeling of CES  
Simulation of selected CES isoform with C2E5, C2E4, C2E3, C2E2, and C2E1 in 
the docking program to generate docking scores. Modeling program, maestro version 9.3, 
was used for simulation. Methods included the preparation of the protein of CES1, grid 
generation, ligand preparation, and docking steps.  
Model Validation and Refinement  
Installing the structure of interested protein, CESs from Protein Data Bank (PDB) 
to Schrodinger Maestro 9.3 program. Human CES crystal (1MX5) was optimized and 
refined. The calculation methods used was simple gradient method and nonlinear 
conjugate gradient method.  
Ligand Design, Protein and Ligand Preparation  
The 2-D sketcher utility of Maestro 9.3 was used to design the structures of ligand 
molecules in two-dimensions, which were then converted into three-dimensional 
structures. Before proceeding with the docking studies, water and other 
hetero-atom groups from the protein structure were removed using protein preparation 
application of Maestro. Ligands were refined with the help of LigPrep to define their 
charged state and their stereo-isomers.  
Modeling Enzyme-ligand Interactions  
C2E5 and its 10 metabolites were docked in the CES binding site cavity of the 
prepared CES. A grid was made by selecting the amino acids at active site (residues) 
involved with the binding of the substrates. Flexible ligand docking was carried out using 
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the standard precision option. Ligands were chosen by Confgen to generate 10000 poses 
per docking run, but write out at most 10 poses per ligand.  
Results 
	  
The preferential bond energy, binding constant and affinity energy were 
calculated based on the hydrodynamics of the enzyme interactions with the molecules. 
Considering the measureable enzymatic parameters, the interactions between ligands and 
protein, the information derived from docking would be able to explain the binding of 
C2E5 to DTPA. C2E1A ligands with top energy preferred structures binding to the active 
sites of 1MX5 (Fig C.1).  In contrast, in order to display the molecular interactions 
between ligands and enzyme, the hydrogen bond was added to the scheme. As a result, 
the top five structures of C2E1 docked with 1MX5 crystal with hydrogen bond 
interactions labeled in-between ligand and metabolic enzyme (Fig C. 2).  Table1 
summarizes the number of poses produced from program for each of the metabolites. 
Finally, figure 3 displays the G-score ranking from high to low: C2E3B, C2E4A, C2E2B, 
C2E2A, DTPA, C2E1A, C2E5, C2E3A, C2E4B, C2E3C, C2E2C, and C2E1B, 
respectively. C2E4A has a preferred gliding score, which makes it a preferred metabolite 
formed during the stepwise hydrolysis in humans.  
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Discussion 
	  
It has reported that similar in silico models used to predict CYP450 and 
transferases metabolism have been established. Some other molecular dynamic methods 
were involved with using simulation to predict the binding of CES substrate to enzyme.  
This study comprises of three major sections. The first one is to choose the proper CES 
crystal structure for docking. Currently, more than 13 experimental structures of hCES1 
are available in PDB data bank. 1MX5 was chosen in this study as the investigated 
carboxylesterase crystal structure because it has the closest chemical properties in 
binding with small molecule as C2E5. The modeling program calculated the optimized 
geometry, in another words, the minimum energy in the conformation, which is the 
integrations of equilibrium bond lengths, bond angles, dihedral (torsional) angles, dipole 
moment and enthalpy of formation.   
C2E3B has lowest gliding score, which means the interaction of C2E3B to the 
enzyme CES costs the lowest bonding energy. However, this is not the case for other 
metabolites. This makes it a preferred metabolite that is formed during the stepwise 
hydrolysis in human. This explains why C2E5 was readily hydrolyzed to C2E4 and C2E3  
in human S9 fractions from liver, intestine and plasma. However, it did not transform 
further into other metabolites. In this study, we did not use rat and dog CES as the model 
enzymes for study the species differences. Therefore, this result is limited to human.  
In the future explorations, additional parameters can be added to calculation of 
scoring system to account for hydrophobic and electrostatic interactions between 
substrates and contributing residues. We could have calculated MLPins score (Molecular 
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Lipophilicity Potential Interaction Score.) in the docking analysis. The application of 
mutual hydrophobic contacts between substrate and enzyme and physicochemical 
properties of each metabolite, for example, solubility and permeability. By accounting for 
those properties, we could generate a more precise estimation in the scoring systems. 
Hence, molecule modeling does have certain limitations to take into considerations; the 
results cannot be used to replace the real experimental results.  However, it can reduce 
redundant experiments and give more insight into the theoretical implications of ester-
based prodrug development.  
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Figure C.1. Top five poses of C2E1A ligands (lowest energy) binding to the active sites 
of human CES crystal (1MX5).  
 
 
 
 
 
 
 
Figure C.1 
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Figure C.2
 
Figure C.2. The interactions of the top five poses of C2E1A with human CES crystal 
(1MX5). THE yellow lines represent the hydrogen bonds formed between compound and 
amino acids.  
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Table C.1.  The number of poses of each C2E5 metabolites calculated from Confgen. 	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Figure C.3. The ranking of G-score indicates the relative affinities of C2E5 metabolites to 
the human CES1.  
	  
-8.5 -8.2 
-8.0 -7.8 
-7.5 -7.5 -7.5 -7.5 -7.5 -7.4 
-6.8 
-9.0 
-8.0 
-7.0 
-6.0 
-5.0 
-4.0 
-3.0 
-2.0 
-1.0 
0.0 C2E3B 
C2E4A 
C2E2B 
C2E2A 
C2E1A 
C2E5 
C2E3A 
C2E4B 
C2E3C 
C2E2C 
C2E1B 
G-score Rankings   
Figure C.3 
